

Contents

Glossary	xii
Acronyms	xiii
1 Introduction	1
1.1 Cancer Research in the Post-Genomic Era	1
1.1.1 Cancer as a Global Health Concern	2
1.1.1.1 The Genetics and Molecular Biology of Cancers	3
1.1.2 The Human Genome Revolution	6
1.1.2.1 The First Human Genome Sequence	6
1.1.2.2 Impact of Genomics	7
1.1.3 Technologies to Enable Genetics Research	7
1.1.3.1 DNA Sequencing and Genotyping Technologies	7
1.1.3.2 Microarrays and Quantitative Technologies	8
1.1.3.3 Massively Parallel “Next Generation” Sequencing . . .	9
1.1.3.3.1 Molecular Profiling with Genomics Technology .	11
1.1.3.3.2 Sequencing Technologies	11
1.1.3.4 Bioinformatics as Interdisciplinary Genomic Analysis .	12
1.1.4 Follow-up Large-Scale Genomics Projects	13
1.1.5 Cancer Genomes	14
1.1.5.1 The Cancer Genome Atlas Project	15
1.1.5.1.1 Findings from Cancer Genomes	15
1.1.5.1.2 Genomic Comparisons Across Cancer Tissues .	17
1.1.5.1.3 Cancer Genomic Data Resources	18
1.1.6 Genomic Cancer Medicine	18
1.1.6.1 Cancer Genes and Driver Mutations	18
1.1.6.2 Personalised or Precision Cancer Medicine	19
1.1.6.2.1 Molecular Diagnostics and Pan-Cancer Medicine	20
1.1.6.3 Targeted Therapeutics and Pharmacogenomics	21
1.1.6.3.1 Targeting Oncogenic Driver Mutations	21
1.1.6.4 Systems and Network Biology	22
1.1.6.4.1 Network Medicine, and Polypharmacology . . .	24
1.2 A Synthetic Lethal Approach to Cancer Medicine	25
1.2.1 Synthetic Lethal Genetic Interactions	26
1.2.2 Synthetic Lethal Concepts in Genetics	26
1.2.3 Studies of Synthetic Lethality	27

1.2.3.1	Synthetic Lethal Pathways and Networks	28
1.2.3.1.1	Evolution of Synthetic Lethality	29
1.2.4	Synthetic Lethal Concepts in Cancer	29
1.2.5	Clinical Impact of Synthetic Lethality in Cancer	31
1.2.6	High-throughput Screening for Synthetic Lethality	33
1.2.6.1	Synthetic Lethal Screens	34
1.2.7	Computational Prediction of Synthetic Lethality	37
1.2.7.1	Bioinformatics Approaches to Genetic Interactions . .	37
1.2.7.2	Comparative Genomics	38
1.2.7.3	Analysis and Modelling of Protein Data	41
1.2.7.4	Differential Gene Expression	43
1.2.7.5	Data Mining and Machine Learning	44
1.2.7.6	Bimodality	47
1.2.7.7	Rationale for Further Development	48
1.3	E-cadherin as a Synthetic Lethal Target	48
1.3.1	The <i>CDH1</i> gene and it's Biological Functions	48
1.3.1.1	Cytoskeleton	49
1.3.1.2	Extracellular and Tumour Micro-Environment	49
1.3.1.3	Cell-Cell Adhesion and Signalling	49
1.3.2	<i>CDH1</i> as a Tumour (and Invasion) Suppressor	50
1.3.2.1	Breast Cancers and Invasion	50
1.3.3	Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer .	50
1.3.4	Somatic Mutations	52
1.3.4.1	Mutation Rate	52
1.3.4.2	Co-occurring Mutations	52
1.3.5	Models of <i>CDH1</i> loss in cell lines	53
1.4	Summary and Research Direction of Thesis	54
2	Methods and Resources	58
2.1	Bioinformatics Resources for Genomics Research	58
2.1.1	Public Data and Software Packages	58
2.1.1.1	Cancer Genome Atlas Data	59
2.1.1.2	Reactome and Annotation Data	60
2.2	Data Handling	61
2.2.1	Normalisation	61
2.2.2	Sample Triage	61
2.2.3	Metagenes and the Singular Value Decomposition	63
2.2.3.1	Candidate Triage and Integration with Screen Data . .	63
2.3	Techniques	64
2.3.1	Statistical Procedures and Tests	64
2.3.2	Gene Set Over-representation Analysis	65
2.3.3	Clustering	66
2.3.4	Heatmap	66
2.3.5	Modeling and Simulations	66
2.3.5.1	Receiver Operating Characteristic (Performance) . . .	67
2.3.6	Resampling Analysis	68

2.4	Pathway Structure Methods	69
2.4.1	Network and Graph Analysis	69
2.4.2	Sourcing Graph Structure Data	70
2.4.3	Constructing Pathway Subgraphs	70
2.4.4	Network Analysis Metrics	70
2.5	Implementation	71
2.5.1	Computational Resources and Linux Utilities	71
2.5.2	R Language and Packages	73
2.5.3	High Performance and Parallel Computing	75
3	Methods Developed During Thesis	77
3.1	A Synthetic Lethal Detection Methodology	77
3.2	Synthetic Lethal Simulation and Modelling	80
3.2.1	A Model of Synthetic Lethality in Expression Data	80
3.2.2	Simulation Procedure	84
3.3	Detecting Simulated Synthetic Lethal Partners	87
3.3.1	Binomial Simulation of Synthetic lethality	87
3.3.2	Multivariate Normal Simulation of Synthetic lethality	89
3.3.2.1	Multivariate Normal Simulation with Correlated Genes	92
3.3.2.2	Specificity with Query-Correlated Pathways	99
3.3.2.2.1	Importance of Directional Testing	99
3.4	Graph Structure Methods	101
3.4.1	Upstream and Downstream Gene Detection	101
3.4.1.1	Permutation Analysis for Statistical Significance	102
3.4.1.2	Hierarchy Based on Biological Context	103
3.4.2	Simulating Gene Expression from Graph Structures	104
3.5	Customised Functions and Packages Developed	108
3.5.1	Synthetic Lethal Interaction Prediction Tool	108
3.5.2	Data Visualisation	109
3.5.3	Extensions to the iGraph Package	111
3.5.3.1	Sampling Simulated Data from Graph Structures	111
3.5.3.2	Plotting Directed Graph Structures	111
3.5.3.3	Computing Information Centrality	112
3.5.3.4	Testing Pathway Structure with Permutation Testing	112
3.5.3.5	Metapackage to Install iGraph Functions	113
4	Synthetic Lethal Analysis of Gene Expression Data	114
4.1	Synthetic lethal genes in breast cancer	115
4.1.1	Synthetic lethal pathways in breast cancer	117
4.1.2	Expression profiles of synthetic lethal partners	118
4.1.2.1	Subgroup pathway analysis	121
4.2	Comparison of synthetic lethal gene candidates	124
4.2.1	Comparison with siRNA screen candidates	124
4.2.1.1	Comparison with correlation	125
4.2.1.2	Comparison with viability	126
4.2.1.3	Comparison with secondary siRNA screen candidates	130

4.2.1.4	Comparison of screen at pathway level	130
4.2.1.4.1	Resampling of genes for pathway enrichment . .	132
4.3	Metagene Analysis	138
4.3.1	Pathway expression	138
4.3.2	Somatic mutation	141
4.3.3	Mutation locus	142
4.3.4	Synthetic lethal metagenes	144
4.4	Replication in stomach cancer	145
4.4.1	Synthetic Lethal Genes and Pathways	146
4.4.2	Synthetic Lethal Expression Profiles	148
4.4.3	Comparison to Primary Screen	150
4.4.3.1	Resampling Analysis	151
4.4.4	Metagene Analysis	151
4.5	Global Synthetic Lethality	152
4.5.1	Hub Genes	153
4.5.2	Hub Pathways	155
4.6	Replication in cell line encyclopaedia	156
4.7	Discussion	158
4.7.1	Strengths of the SLIPT Methodology	158
4.7.2	Synthetic Lethal Pathways for E-cadherin	159
4.7.3	Replication and Validation	161
4.7.3.1	Integration with siRNA Screening	161
4.7.3.2	Replication across Tissues and Cell lines	162
4.8	Summary	163
5	Synthetic Lethal Pathway Structure	166
5.1	Synthetic Lethal Genes in Reactome Pathways	167
5.1.1	The PI3K/AKT Pathway	167
5.1.2	The Extracellular Matrix	169
5.1.3	G Protein Coupled Receptors	172
5.1.4	Gene Regulation and Translation	172
5.2	Network Analysis of Synthetic Lethal Genes	173
5.2.1	Gene Connectivity and Vertex Degree	173
5.2.2	Gene Importance and Centrality	175
5.2.2.1	Information Centrality	175
5.2.2.2	PageRank Centrality	177
5.3	Testing Pathway Structure of Synthetic Lethal Genes	179
5.3.1	Hierarchical Pathway Structure	179
5.3.1.1	Contextual Hierarchy of PI3K	179
5.3.1.2	Testing Contextual Hierarchy of Synthetic Lethal Genes	179
5.3.2	Upstream or Downstream Synthetic Lethality	182
5.3.2.1	Measuring Structure of Candidates within PI3K	183
5.3.2.2	Resampling for Synthetic Lethal Pathway Structure . .	184
5.4	Discussion	186
5.5	Summary	187

6	Simulation and Modeling of Synthetic Lethal Pathways	190
6.1	Comparing methods	191
6.1.1	Performance of SLIPT and χ^2 across Quantiles	192
6.1.1.1	Correlated Query Genes affects Specificity	195
6.1.2	Alternative Synthetic Lethal Detection Strategies	197
6.1.2.1	Correlation for Synthetic Lethal Detection	197
6.1.2.2	Testing for Bimodality with BiSEp	199
6.2	Simulations with Graph Structures	201
6.2.1	Performance over a Graph Structure	202
6.2.1.1	Simple Graph Structures	202
6.2.1.2	Constructed Graph Structures	204
6.2.2	Performance with Inhibitions	208
6.2.3	Synthetic Lethality across Graph Structures	214
6.2.4	Performance within a Simulated Human Genome	218
6.3	Simulations over pathway-based graphs	223
6.3.1	Pathway Structures in a Simulated Human Genome	226
6.4	Discussion	229
6.4.1	Simulation Procedure	229
6.4.2	Design and Performance of SLIPT	230
6.4.3	Simulations from Graph Structures	232
6.5	Summary	233
7	Discussion	237
7.1	Significance	237
7.2	Future Directions	238
7.3	Conclusion	239
8	Conclusion	243
	References	244
A	Sample Quality	261
A.1	Sample Correlation	261
A.2	Replicate Samples in TCGA Breast	264
B	Software Used for Thesis	268
C	Secondary Screen Data	277
D	Mutation Analysis in Breast Cancer	279
D.1	Synthetic Lethal Genes and Pathways	279
D.2	Synthetic Lethal Expression Profiles	282
D.3	Comparison to Primary Screen	285
D.3.1	Resampling Analysis	287
D.4	Compare SLIPT genes	289
D.5	Metagene Analysis	291
D.6	Mutation Variation	292

D.6.1	Mutation Frequency	292
D.6.2	PI3K Mutation Expression	293
E	Metagene Expression Profiles	296
F	Stomach Expression Analysis	302
F.1	Synthetic Lethal Genes and Pathways	302
F.2	Comparison to Primary Screen	305
F.2.1	Resampling Analysis	307
F.3	Metagene Analysis	309
G	Stomach Mutation Analysis	310
G.1	Synthetic Lethal Genes and Pathways	310
G.2	Synthetic Lethal Expression Profiles	313
G.3	Comparison to Primary Screen	316
G.3.1	Resampling Analysis	318
G.4	Metagene Analysis	320
H	Global Synthetic Lethality in Stomach Cancer	321
H.1	Hub Genes	323
H.2	Hub Pathways	324
I	Replication in cell line encyclopaedia	325

List of Figures

1.1	Synthetic genetic interactions	27
1.2	Synthetic lethality in cancer	30
2.1	Read count density	62
2.2	Read count sample mean	62
3.1	Framework for synthetic lethal prediction	78
3.2	Synthetic lethal prediction adapted for mutation	79
3.3	A model of synthetic lethal gene expression	81
3.4	Modeling synthetic lethal gene expression	82
3.5	Synthetic lethality with multiple genes	83
3.6	Simulating gene function	85
3.7	Simulating synthetic lethal gene function	85
3.8	Simulating synthetic lethal gene expression	86
3.9	Performance of binomial simulations	88
3.10	Comparison of statistical performance	88
3.11	Performance of multivariate normal simulations	90
3.12	Simulating expression with correlated gene blocks	93
3.13	Simulating expression with correlated gene blocks	94
3.14	Synthetic lethal prediction across simulations	95
3.15	Performance with correlations	96
3.16	Comparison of statistical performance with correlation structure	97
3.17	Performance with query correlations	98
3.18	Statistical evaluation of directional criteria	99
3.19	Performance of directional criteria	100
3.20	Simulated graph structures	104
3.21	Simulating expression from a graph structure	106
3.22	Simulating expression from graph structure with inhibitions	107
3.23	Demonstration of violin plots with custom features	110
3.24	Demonstration of annotated heatmap	110
3.25	Simulating graph structures	112
4.1	Synthetic lethal expression profiles of analysed samples	120
4.2	Comparison of SLIPT to siRNA	124
4.3	Compare SLIPT and siRNA genes with correlation	125
4.4	Compare SLIPT and siRNA genes with correlation	125
4.5	Compare SLIPT and siRNA genes with siRNA viability	127

4.6	Compare SLIPT and siRNA genes with viability	127
4.7	Compare SLIPT and siRNA genes with siRNA viability	129
4.8	Resampled intersection of SLIPT and siRNA candidates	133
4.9	Pathway metagene expression profiles	139
4.10	Somatic mutation against PI3K metagene	141
4.11	Somatic mutation locus against expression	143
4.12	Synthetic lethal expression profiles of stomach samples	149
4.13	Synthetic lethal partners across query genes	153
5.1	Synthetic Lethality in the PI3K Cascade	168
5.2	Synthetic Lethality in the Elastic Fibre Formation Pathway	170
5.3	Synthetic Lethality in the Fibrin Clot Formation	171
5.4	Synthetic Lethality and Vertex Degree	174
5.5	Synthetic Lethality and Centrality	176
5.6	Synthetic Lethality and PageRank	178
5.7	Structure of PI3K Ranking	180
5.8	Synthetic Lethality and Hierarchy Score in PI3K	181
5.9	Hierarchy Score in PI3K against Synthetic Lethality in PI3K	181
5.10	Structure of Synthetic Lethality in PI3K	182
5.11	Structure of Synthetic Lethality Resampling in PI3K	183
6.1	Performance of χ^2 and SLIPT across quantiles	193
6.2	Performance of χ^2 and SLIPT across quantiles with more genes	194
6.3	Performance of χ^2 and SLIPT across quantiles with query correlation	195
6.4	Performance of χ^2 and SLIPT across quantiles with query correlation and more genes	196
6.5	Performance of negative correlation and SLIPT	198
6.6	Performance of simulations on a simple graph	203
6.7	Performance of simulations is similar in simple graphs	204
6.8	Performance of simulations on a constructed graph	205
6.9	Performance of simulations on a large graph	207
6.10	Performance of simulations on a simple graph with inhibition	209
6.11	Performance is higher on a simple inhibiting graph	210
6.12	Performance of simulations on a constructed graph with inhibition	212
6.13	Performance is affected by inhibition in graphs	213
6.14	Detection of Synthetic Lethality within a Graph Structure	215
6.15	Detection of Synthetic Lethality within a Graph Structure with Inhibitions	217
6.16	Performance of simulations including a simple graph	219
6.17	Performance on a simple graph improves with more genes	220
6.18	Performance on an inhibiting graph with more genes	221
6.19	Performance on an inhibiting graph improves with more genes	223
6.20	Performance of simulations on the PI3K cascade	225
6.21	Performance of simulations including the PI3K cascade	227
6.22	Performance on pathways improves with more genes	228
A.1	Correlation profiles of removed samples	262

A.2	Correlation analysis and sample removal	263
A.3	Replicate excluded samples	264
A.4	Replicate samples with all remaining	265
A.5	Replicate samples with some excluded	266
D.1	Synthetic lethal expression profiles of analysed samples	283
D.2	Comparison of mtSLIPT to siRNA	285
D.3	Compare mtSLIPT and siRNA genes with correlation	289
D.4	Compare mtSLIPT and siRNA genes with correlation	289
D.5	Compare mtSLIPT and siRNA genes with siRNA viability	290
D.6	Somatic mutation locus	292
D.7	Somatic mutation against PIK3CA metagene	293
D.8	Somatic mutation against PI3K protein	294
D.9	Somatic mutation against AKT protein	295
E.1	Pathway metagene expression profiles	297
E.2	Expression profiles for constituent genes of PI3K	298
E.3	Expression profiles for p53 related genes	299
E.4	Expression profiles for estrogen receptor related genes	300
E.5	Expression profiles for BRCA related genes	301
F.1	Comparison of SLIPT in stomach to siRNA	305
G.1	Synthetic lethal expression profiles of stomach samples	314
G.2	Comparison of mtSLIPT in stomach to siRNA	316
H.1	Synthetic lethal partners across query genes	322

List of Tables

1.1	Methods for Predicting Genetic Interactions	38
1.2	Methods for Predicting Synthetic Lethality in Cancer	39
1.3	Methods used by Wu <i>et al.</i> (2014)	40
2.1	Excluded Samples by Batch and Clinical Characteristics.	63
2.2	Computers used during Thesis	72
2.3	Linux Utilities and Applications used during Thesis	72
2.4	R Installations used during Thesis	73
2.5	R Packages used during Thesis	73
2.6	R Packages Developed during Thesis	75
4.1	Candidate synthetic lethal gene partners of <i>CDH1</i> from SLIPT	116
4.2	Pathways for <i>CDH1</i> partners from SLIPT	118
4.3	Pathway composition for clusters of <i>CDH1</i> partners from SLIPT	122
4.4	Pathway composition for <i>CDH1</i> partners from SLIPT and siRNA screen- ing	131
4.5	Pathways for <i>CDH1</i> partners from SLIPT	135
4.6	Pathways for <i>CDH1</i> partners from SLIPT and siRNA primary screen .	136
4.7	Candidate synthetic lethal metagenes against <i>CDH1</i> from SLIPT	145
4.8	Pathways for <i>CDH1</i> partners from SLIPT in stomach cancer	147
4.9	Query synthetic lethal genes with the most SLIPT partners	154
4.10	Pathways for genes with the most SLIPT partners	155
4.11	Pathways for <i>CDH1</i> partners from SLIPT in CCLE	156
4.12	Pathways for <i>CDH1</i> partners from SLIPT in breast CCLE	158
5.1	analysis of variance (ANOVA) for Synthetic Lethality and Vertex Degree	175
5.2	ANOVA for Synthetic Lethality and Information Centrality	177
5.3	ANOVA for Synthetic Lethality and PageRank Centrality	178
5.4	ANOVA for Synthetic Lethality and PI3K Hierarchy	181
5.5	Resampling for pathway structure of synthetic lethal detection methods	185
B.1	R Packages used during Thesis	268
C.1	Comparing SLIPT genes against Secondary siRNA Screen in breast cancer	277
C.2	Comparing mtSLIPT genes against Secondary siRNA Screen in breast cancer	278
C.3	Comparing SLIPT genes against Secondary siRNA Screen in stomach cancer	278

D.1	Candidate synthetic lethal gene partners of <i>CDH1</i> from mtSLIPT . . .	280
D.2	Pathways for <i>CDH1</i> partners from mtSLIPT	281
D.3	Pathway composition for clusters of <i>CDH1</i> partners from mtSLIPT . .	284
D.4	Pathway composition for <i>CDH1</i> partners from mtSLIPT and siRNA . .	286
D.5	Pathways for <i>CDH1</i> partners from mtSLIPT	287
D.6	Pathways for <i>CDH1</i> partners from mtSLIPT and siRNA primary screen	288
D.7	Candidate synthetic lethal metagenes against <i>CDH1</i> from mtSLIPT . .	291
F.1	Synthetic lethal gene partners of <i>CDH1</i> from SLIPT in stomach cancer	303
F.2	Pathway composition for clusters of <i>CDH1</i> partners in stomach SLIPT	304
F.3	Pathway composition for <i>CDH1</i> partners from SLIPT and siRNA screen- ing	306
F.4	Pathways for <i>CDH1</i> partners from SLIPT in stomach cancer	307
F.5	Pathways for <i>CDH1</i> partners from SLIPT in stomach and siRNA screen	308
F.6	Candidate synthetic lethal metagenes against <i>CDH1</i> from SLIPT in stomach cancer	309
G.1	Synthetic lethal gene partners of <i>CDH1</i> from mtSLIPT in stomach cancer	311
G.2	Pathways for <i>CDH1</i> partners from mtSLIPT in stomach cancer	312
G.3	Pathway composition for clusters of <i>CDH1</i> partners in stomach mtSLIPT	315
G.4	Pathway composition for <i>CDH1</i> partners from mtSLIPT and siRNA . .	317
G.5	Pathways for <i>CDH1</i> partners from mtSLIPT in stomach cancer	318
G.6	Pathways for <i>CDH1</i> partners from mtSLIPT in stomach and siRNA screen	319
G.7	Candidate synthetic lethal metagenes against <i>CDH1</i> from mtSLIPT in stomach cancer	320
H.1	Query synthetic lethal genes with the most SLIPT partners	323
H.2	Pathways for genes with the most SLIPT partners	324
I.1	Candidate synthetic lethal gene partners of <i>CDH1</i> from SLIPT in CCLE	326
I.2	Candidate synthetic lethal gene partners of <i>CDH1</i> from SLIPT in breast CCLE	327
I.3	Candidate synthetic lethal gene partners of <i>CDH1</i> from SLIPT in stom- ach CCLE	328
I.4	Pathways for <i>CDH1</i> partners from SLIPT in stomach CCLE	329
I.5	Pathways for <i>CDH1</i> partners from SLIPT in breast and stomach CCLE	329

Glossary

synthetic lethal Genetic interactions where inactivation of multiple genes is inviable (or deleterious) when they are viable if inactivated separately.

Acronyms

siRNA Short interfering ribonucleic acid.
SLIPT Synthetic lethal interaction prediction tool.

Chapter 4

Synthetic Lethal Analysis of Gene Expression Data

Having developed a statistical synthetic lethal detection methodology (Synthetic Lethal Interaction Prediction Tool (SLIPT)), it was applied to empirical (publicly available) cancer gene expression datasets in this Chapter. The analysis largely focuses findings from the TCGA breast cancer data (TCGA, 2012) which covers a range of clinical subtypes and is more closely modelled by short interfering ribonucleic acid (siRNA) data (Telford *et al.*, 2015) generated from screening experiments conducted in MCF10A breast cells. Although stomach cancer data will also be considered to replicate findings in an independent dataset and for its relevance to syndromic hereditary diffuse gastric cancer. The TCGA data also has the advantages of other clinical and molecular profiles (e.g., somatic mutation and DNA copy number) for many of the same samples, in addition to a considerable sample size for RNASeq expression data, treated with a rigorous procedure to minimise batch effects. Some findings will be replicated in the Cancer Cell Line Encyclopaedia (CCLE) (Barretina *et al.*, 2012) which may be more comparable to the cell line experiments.

Synthetic lethal candidate partners for *CDH1* will be described at both the gene and pathway level. SLIPT gene candidates will be analysed by cluster analysis for common expression profiles across samples and relationships with clinical factors and mutations in key breast cancer genes. These genes will also be compared to the gene candidates from a primary and secondary (validation) screens conducted by Telford *et al.* (2015) on isogenic cell lines. For comparison, an alternative SLIPT methodology which uses mutation data for *CDH1* against expression of candidate partners will also be presented which may better represent the null mutations in HDGC patients

and the experiment cell model (Chen *et al.*, 2014). Pathways will be analysed by over-representation analysis (with resampling for comparisons with siRNA data) and supported by a metagene analysis of pathway gene signatures. The pathway metagene expression profiles will be used to replicate known relationships between clinical and molecular characteristics for breast cancer and to demonstrate application of SLIPT directly on metagenes to detect synthetic lethal pathways.

Together these results will demonstrate the wide range of applications for SLIPT analysis and examine the synthetic lethal partners of *CDH1* in breast and stomach cancer. These synthetic lethal genes and pathways will be described in both context of the functional implications of novel synthetic lethal relationships and as potential actionable targets against *CDH1* deficient tumours, in addition to replication of established functions of E-cadherin. In particular, the focus of these analysis will be in comparisons with experimental screening data to explore the potential for SLIPT to augment such triage of candidate partners and support further experimental investigations. The key synthetic lethal partner pathways for *CDH1*, supported by both approaches, will be examined in more detail at the gene and pathway structure level in Chapter 5.

Some of the findings presented in this Chapter have also been included in manuscripts submitted for publication (Kelly *et al.*, 2017a,b) and may bear similarity to them, although the results in this thesis have been edited to cohesively fit with additional findings (including consistent data versions). These findings are the result of investigations conducted throughout this thesis project and only these contributions to the articles are included in this Chapter, not that conducted by co-authors.

4.1 Synthetic lethal genes in breast cancer

The SLIPT methodology (as described in Section 3.1) was applied to the normalised TCGA breast cancer gene expression dataset ($n = 1168$). As shown in Table 4.1, the most significant genes had strong evidence of expression-based association with *CDH1* (high χ^2 values) with fewer samples exhibiting low expression of both genes than expected statistically. Eukaryotic translation gene were among the highest gene candidates, including initiation factors, elongation factors, and ribosomal proteins. These are clearly necessary for cancer cells to grow and proliferate, with sustained gene expression needed to maintain growth signaling pathways and resist apoptosis or immune factors translation may be subject to non-oncogene addiction for *CDH1*-deficient cells.

While these are among the strongest synthetic lethal candidates, translational genes are crucial to the viability of healthy cells and dosing for a selective synthetic lethal effect against these may be difficult compared to other biological functions which may also be supported among the SLIPT candidate genes. Furthermore, few known biological functions of *CDH1* were among the strongest SL candidates so the remaining candidate genes may also be informative since they are likely to contain these expected functions in addition to novel relationships for *CDH1*. Thus further pathway level analyses were also conducted to examine biological functions over-represented among synthetic candidate genes and identify synthetic lethal pathways.

Table 4.1: Candidate synthetic lethal gene partners of *CDH1* from SLIPT

Gene	Observed	Expected	χ^2 value	p-value	p-value (FDR)
<i>TRIP10</i>	62	130	162	5.65×10^{-34}	1.84×10^{-31}
<i>EEF1B2</i>	56	130	158	3.10×10^{-33}	9.45×10^{-31}
<i>GBGT1</i>	61	131	156	1.08×10^{-32}	3.14×10^{-30}
<i>ELN</i>	81	130	149	3.46×10^{-31}	8.82×10^{-29}
<i>TSPAN4</i>	78	130	146	1.63×10^{-30}	3.79×10^{-28}
<i>GLIPR2</i>	72	130	146	1.68×10^{-30}	3.86×10^{-28}
<i>RPS20</i>	73	131	145	1.89×10^{-30}	4.28×10^{-28}
<i>RPS27A</i>	80	130	143	5.53×10^{-30}	1.18×10^{-27}
<i>EEF1A1P9</i>	63	130	141	1.91×10^{-29}	3.74×10^{-27}
<i>C1R</i>	73	130	141	2.05×10^{-29}	3.97×10^{-27}
<i>LYL1</i>	73	130	140	2.99×10^{-29}	5.74×10^{-27}
<i>RPLP2</i>	71	130	139	4.88×10^{-29}	9.07×10^{-27}
<i>C10orf10</i>	73	130	138	6.72×10^{-29}	1.20×10^{-26}
<i>DULLARD</i>	74	131	138	9.29×10^{-29}	1.61×10^{-26}
<i>PPM1F</i>	64	130	136	1.61×10^{-28}	2.65×10^{-26}
<i>OBFC2A</i>	69	130	136	2.49×10^{-28}	3.93×10^{-26}
<i>RPL11</i>	70	130	136	2.56×10^{-28}	3.97×10^{-26}
<i>RPL18A</i>	70	130	135	3.08×10^{-28}	4.70×10^{-26}
<i>MFNG</i>	76	131	133	7.73×10^{-28}	1.12×10^{-25}
<i>RPS17</i>	77	131	133	8.94×10^{-28}	1.29×10^{-25}
<i>MGAT1</i>	73	130	132	1.44×10^{-27}	2.03×10^{-25}
<i>RPS12</i>	72	130	128	8.57×10^{-27}	1.12×10^{-24}
<i>C10orf54</i>	73	130	127	1.37×10^{-26}	1.75×10^{-24}
<i>LOC286367</i>	72	130	126	2.20×10^{-26}	2.70×10^{-24}
<i>GMFG</i>	70	130	126	2.20×10^{-26}	2.70×10^{-24}

Strongest candidate SL partners for *CDH1* by SLIPT with observed and expected samples with low expression of both genes

The modified mtSLIPT methodology (as described in Section 3.1) was also applied to the normalised TCGA breast cancer gene expression dataset, against somatic loss of function mutations in *CDH1*. As shown in Table D.1, the most significant genes also had strong evidence of expression associated with *CDH1* mutations (high χ^2 values) with fewer samples exhibiting both low expression and mutations of each gene than expected statistically. Although, these were not as strongly supported as the expression analysis (in Table 4.1) nor were as many genes detected. This is unsurprising due to the lower sample size with matching somatic mutation data and the lower frequency of *CDH1* mutations compared to low expression by $1/3$ quantiles.

The mtSLIPT candidates had more genes involved in cell and gene regulation, particularly DNA and RNA binding factors. The strongest candidates also include microtubule (*KIF12*), microfibril (*MFAP4*), and cell adhesion (*TENC1*) genes consistent with the established cytoskeletal role of *CDH1*. The elastin gene (*ELN*) was notably strongly supported by both expression and mutation SLIPT analysis of *CDH1* supporting a interactions with extracellular proteins and the tumour microenvironment.

4.1.1 Synthetic lethal pathways in breast cancer

Translational pathways were strongly over-represented in SLIPT partners, as shown in Table 4.2. These include ribosomal subunits, initiation, peptide elongation, and termination. Regulatory processes involving mRNA including 3' untranslated region (UTR) binding, L13a-mediated translational silencing, and nonsense-mediated decay were also implicated. These are consistent with protein translation being subject to “non-oncogene addiction” (Luo *et al.*, 2009), as a core process that is dysregulated to sustain cancer proliferation and survival (Gao and Roux, 2015).

Immune pathways, including the adaptive immune system and responses to infectious diseases were also strongly implicated as synthetic lethal with loss of E-cadherin. This is consistent with the alterations of immune response being a hallmark of cancer Hanahan and Weinberg (2000), since evading the immune system is necessary for cancer survival. Either of these systems are potential means to target *CDH1* deficient cells, although these were not detected in an isolated cell line experimental screen (Telford *et al.*, 2015) and the differences between to findings in patient data will be described in more detail in Section 4.2.1.4.

It is also notable that the pathways over-represented in SLIPT candidate genes have strongly significant over-representation of Reactome pathways from the hypergeometric test (as described in Section 2.3.2). Even after adjusting stringently for multiple tests,

Table 4.2: Pathways for *CDH1* partners from SLIPT

Pathways Over-represented	Pathway Size	SL Genes	p-value (FDR)
Eukaryotic Translation Elongation	86	81	1.3×10^{-207}
Peptide chain elongation	83	78	5.6×10^{-201}
Eukaryotic Translation Termination	83	77	1.2×10^{-196}
Viral mRNA Translation	81	76	1.2×10^{-196}
Formation of a pool of free 40S subunits	93	81	3.7×10^{-194}
Nonsense Mediated Decay independent of the Exon Junction Complex	88	77	5.3×10^{-187}
L13a-mediated translational silencing of Ceruloplasmin expression	103	82	9.6×10^{-183}
3' -UTR-mediated translational regulation	103	82	9.6×10^{-183}
GTP hydrolysis and joining of the 60S ribosomal subunit	104	82	1.9×10^{-181}
Nonsense-Mediated Decay	103	80	6.2×10^{-176}
Nonsense Mediated Decay enhanced by the Exon Junction Complex	103	80	6.2×10^{-176}
Adaptive Immune System	412	167	6.5×10^{-174}
Eukaryotic Translation Initiation	111	82	5.7×10^{-173}
Cap-dependent Translation Initiation	111	82	5.7×10^{-173}
SRP-dependent cotranslational protein targeting to membrane	104	79	2.0×10^{-171}
Translation	141	91	6.1×10^{-170}
Infectious disease	347	146	1.6×10^{-166}
Influenza Infection	117	81	1.9×10^{-163}
Influenza Viral RNA Transcription and Replication	108	77	1.9×10^{-160}
Influenza Life Cycle	112	77	2.5×10^{-156}

Gene set over-representation analysis (hypergeometric test) for Reactome pathways in SLIPT partners for *CDH1*

biologically related pathways give consensus support to these pathways. These pathways are further supported by testing for synthetic lethality against *CDH1* mutations (mtSLIPT) with many of these pathways also among the most strongly supported in this analysis (shown in Table D.2). This analysis more closely represents the null *CDH1* mutations in HDGC (Guilford *et al.*, 1998) and the experimental MCF10A cell model (Chen *et al.*, 2014). Although it still supports translational and immune pathways not detected in the isolated experimental system, G-protein-coupled receptors (GPCRs) were also among the most strongly supported pathways, supporting the experimental findings of Telford *et al.* (2015) for these intracellular signalling pathways already being targeted for other diseases.

4.1.2 Expression profiles of synthetic lethal partners

Due to the sheer number of gene candidates and to examine their expression patterns, investigations proceeded into correlation structure and pathway over-representation. This serves to explore the functional similarity of the synthetic lethal partners of *CDH1*, with the eventual aim to assess their utility as drug targets. As shown in Figure 4.1 (which clusters *CDH1* lowly expressing samples separately), there were several large

clusters of genes among the expression profiles of the *CDH1* synthetic lethal candidate partners. The clustering suggests co-regulation of genes or pathway correlation between partner gene candidates. A number of candidates from an experimental RNAi screen study performed by Telford *et al.* (2015) were also identified by this approach. In addition, we identified novel gene candidates, which had little effect on viability in isogenic cell line experiments.

In these expression profiles, a gene with a moderate or high signal across samples exhibiting low *CDH1* expression would represent a potential drug target. However, it appears that several molecular subtypes of cancer have elevation of different clusters of synthetic lethal candidates in samples with low *CDH1*. This clustering suggests that different targets or combinations could be effective in different patients suggesting potential utility for stratification. In particular, estrogen receptor negative, basal subtype, and “normal-like” samples Dai *et al.* (2015); Eroles *et al.* (2012); Parker *et al.* (2009) have elevation of genes specific to particular clusters which is indicative of some synthetic lethal interactions being specific to a particular molecular subtype or genetic background. Thus synthetic lethal drug therapy against these subtypes may be ineffective if it were designed against genes in another cluster.

A similar correlation structure was observed among the candidates tested against *CDH1* mutation (mtSLIPT), as shown in Figure D.1. This clustering analysis similarly identified several major clusters of putative synthetic lethal partner genes. Although in this case many partner genes had consistently high expression across most of the (predominantly lobular subtype) *CDH1* breast cancer samples. However, a major exception to this in the *CDH1* expression analysis were the normal samples which were excluded from the mutation data (as they were not tested for tumour-specific genotypes). This supports synthetic lethal interventions being more applicable to *CDH1* mutant tumours and genotyping tumours for loss of function will be essential for clinical application. There was still considerable correlation structure, particularly among *CDH1* wildtype samples, sufficient to distinguish gene clusters. In contrast to the expression analysis the (predominantly ductal *CDH1* wildtype) basal subtype and estrogen receptor negative samples have depleted expression among most candidate synthetic lethal partners. This is consistent with synthetic lethal interventions only being effective in lobular estrogen receptor positive breast cancers in which they are a more common, as recurrent (driver) mutation. However, the remaining samples are still informative for synthetic lethal analysis (by SLIPT) as it requires highly expressing *CDH1* samples for comparison.




Figure 4.1: Synthetic lethal expression profiles of analysed samples. Gene expression profile heatmap (correlation distance) of all samples (separated by the $1/3$ quantile of *CDH1* expression) analysed in TCGA breast cancer dataset for gene expression of 5,165 candidate partners of E-cadherin (*CDH1*) from SLIPT prediction (with significant FDR adjusted $p < 0.05$). Deeply clustered, inter-correlated genes form several main groups, each containing genes that were SL candidates or toxic in an siRNA screen Telford *et al.* (2015). Clusters had different sample groups highly expressing the synthetic lethal candidates in *CDH1* low samples, notably ‘normal-like’, basal, and estrogen receptor negative samples have elevated expression in one or more distinct clusters showing complexity and variation among candidate synthetic lethal partners. *CDH1* low samples also contained most of samples with *CDH1* mutations.

The *CDH1* mutant samples (in Figure 4.1) were predominantly among the *CDH1* lowly expressing samples and distributed throughout *CDH1* samples with clustering analysis. Thus the molecular profiles of *CDH1* low samples are indistinguishable from *CDH1* mutant samples with the exception of normal samples (that do not have somatic mutation data as it is inferred from comparison to them to tumour-specific genotypes). Conversely, many of the *CDH1* mutant samples (in Figure D.1) had among the lowest *CDH1* expression and some of the synthetic lethal partners were also highly expressed in lowly expressing *CDH1* wildtype samples, despite these not being considered as “inactivated” by mtSLIPT analysis.

Together these results support the use for low *CDH1* expression as a strategy for detecting *CDH1* inactivation. This has the benefit of increasing sample size (including samples such as normal tissue which do not have somatic mutation data available) and increasing the expected number of mutually inactive (low-low) samples for the directional criteria of (mt)SLIPT which enabling it to better distinguish significant deviations below this (as discussed in Section ??). This also circumvents the assumption that all (detected) mutations are inactivating (although synonymous mutations were excluded from the analysis), which may not be the case for several highly expressing *CDH1* mutant samples that do not cluster together in Figures 4.1 or D.1. One of these exhibits among the lowest expression for many predicted synthetic lethal partners and would not be vulnerable to inactivation of these genes. As such correctly genotyping inactivating mutations will be essential in clinical practice for synthetic lethal targeting tumour suppressor genes, particularly for other genes such as *TP53* where oncogenic and tumour suppressor mutations (with different molecular consequences) are both common in cancers. Using expression as a measure of gene expression also avoids the assumptions that mutations are somatic rather than germline and that gene inactivation is by detectable mutations rather than other mechanisms such as epigenetic changes which is supported by many lowly expressing *CDH1* wildtype samples clustering with similar profiles to mutant samples.

4.1.2.1 Subgroup pathway analysis

Synthetic lethal gene candidates for *CDH1* from SLIPT performed on RNA-Seq expression data were also used for pathway over-representation analyses (as described in Section 2.3.2). The correlation structure in the expression of candidate synthetic lethal genes in *CDH1* low tumours (lowest $\frac{1}{3}$ rd quantile of expression) was examined for distinct biological pathways in subgroups of genes elevated in different clusters of samples. These genes were highly expressed in different samples with their clinical fac-

Table 4.3: Pathway composition for clusters of *CDH1* partners from SLIPT

Pathways Over-represented in Cluster 1	Pathway Size	Cluster Genes	p-value (FDR)
Collagen formation	67	10	4.0×10^{-11}
Extracellular matrix organisation	238	21	1.8×10^{-9}
Collagen biosynthesis and modifying enzymes	56	8	1.8×10^{-9}
Uptake and actions of bacterial toxins	22	5	9.5×10^{-9}
Elastic fibre formation	37	6	1.9×10^{-8}
Muscle contraction	62	7	2.4×10^{-7}
Fatty acid, triacylglycerol, and ketone body metabolism	117	10	4.9×10^{-7}
XBP1(S) activates chaperone genes	51	6	6.6×10^{-7}
IRE1alpha activates chaperones	54	6	1.2×10^{-6}
Neurotoxicity of clostridium toxins	10	3	1.3×10^{-6}
Retrograde neurotrophin signalling	10	3	1.3×10^{-6}
Assembly of collagen fibrils and other multimeric structures	40	5	1.9×10^{-6}
Collagen degradation	58	6	2.0×10^{-6}
Arachidonic acid metabolism	41	5	2.1×10^{-6}
Synthesis of PA	26	4	3.0×10^{-6}
Signaling by NOTCH	80	7	3.3×10^{-6}
Signalling to RAS	27	4	3.7×10^{-6}
Integrin cell surface interactions	82	7	4.2×10^{-6}
Smooth Muscle Contraction	28	4	4.4×10^{-6}
ECM proteoglycans	66	6	6.3×10^{-6}

Pathways Over-represented in Cluster 2	Pathway Size	Cluster Genes	p-value (FDR)
Eukaryotic Translation Elongation	86	75	1.1×10^{-181}
Viral mRNA Translation	81	72	9.8×10^{-179}
Peptide chain elongation	83	72	1.9×10^{-175}
Eukaryotic Translation Termination	83	72	1.9×10^{-175}
Formation of a pool of free 40S subunits	93	75	1.9×10^{-171}
Nonsense Mediated Decay independent of the Exon Junction Complex	88	72	9.9×10^{-168}
LI3a-mediated translational silencing of Ceruloplasmin expression	103	75	3.0×10^{-159}
3' -UTR-mediated translational regulation	103	75	3.0×10^{-159}
Nonsense-Mediated Decay	103	75	3.0×10^{-159}
Nonsense Mediated Decay enhanced by the Exon Junction Complex	103	75	3.0×10^{-159}
SRP-dependent cotranslational protein targeting to membrane	104	75	3.2×10^{-158}
GTP hydrolysis and joining of the 60S ribosomal subunit	104	75	3.2×10^{-158}
Eukaryotic Translation Initiation	111	75	4.5×10^{-151}
Cap-dependent Translation Initiation	111	75	4.5×10^{-151}
Influenza Infection	117	75	1.4×10^{-145}
Influenza Viral RNA Transcription and Replication	108	72	5.7×10^{-145}
Translation	141	81	8.0×10^{-143}
Influenza Life Cycle	112	72	2.3×10^{-141}
Infectious disease	347	103	2.2×10^{-95}
Formation of the ternary complex, and subsequently, the 43S complex	47	33	6.8×10^{-80}

Pathways Over-represented in Cluster 3	Pathway Size	Cluster Genes	p-value (FDR)
Adaptive Immune System	412	90	6.1×10^{-61}
Chemokine receptors bind chemokines	52	27	6.7×10^{-56}
Generation of second messenger molecules	29	21	6.5×10^{-55}
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	64	29	6.5×10^{-55}
TCR signalling	62	27	8.9×10^{-51}
Peptide ligand-binding receptors	161	40	1.5×10^{-45}
Translocation of ZAP-70 to Immunological synapse	16	14	3.1×10^{-43}
Costimulation by the CD28 family	51	22	4.0×10^{-43}
PD-1 signalling	21	15	4.0×10^{-41}
Class A/1 (Rhodopsin-like receptors)	258	50	6.7×10^{-41}
Phosphorylation of CD3 and TCR zeta chains	18	14	1.3×10^{-40}
Interferon gamma signalling	74	24	5.0×10^{-39}
GPCR ligand binding	326	57	1.8×10^{-38}
Cytokine Signaling in Immune system	268	48	8.9×10^{-37}
Downstream TCR signalling	45	18	1.8×10^{-35}
G _α signalling events	167	33	2.2×10^{-33}
Cell surface interactions at the vascular wall	99	21	1.3×10^{-26}
Interferon Signalling	164	28	1.7×10^{-26}
Extracellular matrix organisation	238	35	2.7×10^{-25}
Antigen activates B Cell Receptor leading to generation of second messengers	32	12	7.2×10^{-25}

Pathways Over-represented in Cluster 4	Pathway Size	Cluster Genes	p-value (FDR)
Extracellular matrix organisation	238	48	8.0×10^{-41}
Class A/1 (Rhodopsin-like receptors)	258	47	2.8×10^{-36}
GPCR ligand binding	326	54	2.1×10^{-34}
G _α signalling events	83	22	1.4×10^{-31}
GPCR downstream signalling	472	68	1.1×10^{-29}
Haemostasis	423	61	3.3×10^{-29}
Platelet activation, signalling and aggregation	180	31	7.1×10^{-28}
Binding and Uptake of Ligands by Scavenger Receptors	40	14	9.9×10^{-27}
RA biosynthesis pathway	22	11	2.5×10^{-26}
Response to elevated platelet cytosolic Ca ²⁺	82	19	3.0×10^{-26}
Developmental Biology	420	57	3.5×10^{-26}
G _α signalling events	167	28	7.3×10^{-26}
Platelet degranulation	77	18	1.6×10^{-25}
Gastrin-CREB signalling pathway via PKC and MAPK	171	28	2.5×10^{-25}
Muscle contraction	62	16	4.7×10^{-25}
G _α signalling events	150	25	3.2×10^{-24}
Retinoid metabolism and transport	34	12	5.0×10^{-24}
Phase 1 - Functionalisation of compounds	67	16	6.5×10^{-24}
Signalling by Retinoic Acid	42	13	6.7×10^{-24}
Degradation of the extracellular matrix	102	19	1.4×10^{-22}

tors including estrogen receptor status and intrinsic (PAM50) subtype (Parker *et al.*, 2009) shown in Figure 4.1.

As shown by the most over-represented pathways in Table 4.3, each correlated cluster of candidate synthetic lethal partners of *CDH1* contains functionally different genes. Cluster 1 contains genes with less evidence of over-represented pathways than other clusters, corresponding to less correlation between genes within the cluster, and to it being a relatively small group. While there is some indication that collagen biosynthesis, microfibril elastic fibres, extracellular matrix, and metabolic pathways may be over-represented in Cluster 1, these results are mainly based on small pathways containing few synthetic lethal genes. Genes in Cluster 2 exhibited low expression in normal tissue samples compared to tumour samples (see Figure 4.1) and show compelling evidence of over-representation of post-transcriptional gene regulation and protein translation processes. Similarly, Cluster 3 has over-representation of immune signalling pathways (including chemokines, secondary messenger, and TCR signaling) and downstream intracellular signalling cascades such as G protein coupled receptor (GPCR) and $G_{\alpha i}$ signalling events. While pathway over-representation was weaker among genes in Cluster 4, they contained intracellular signalling pathways and were highly expressed in normal samples (in contrast to Cluster 2). Cluster 4 also involved extracellular factors and stimuli such as extracellular matrix, platelet activation, ligand receptors, and retinoic acid signalling.

Based on these results, potential synthetic lethal partners of *CDH1* include processes known to be dysregulated in cancer, such as translational, cytoskeletal, and immune processes. Intracellular signalling cascades such as the GPCRs and extracellular stimuli for these pathways were also implicated in potential synthetic lethality with *CDH1*.


Similar translational, cytoskeletal, and immune processes were identified among SLIPT partners with respect to *CDH1* mutation, shown in Table D.3. While GPCR signalling was replicated in mtSLIPT analysis, there was also stronger over-representation for NOTCH, ERBB2, and PI3K/AKT signalling in mutation analysis consistent with these signals being important for proliferation of *CDH1* deficient tumours. The GPCR and PI3K/AKT pathways are of particular interest as pathways with oncogenic mutations that can be targeted and downstream effects on translation (a strongly supported process across analyses). Extracellular matrix pathways (such as elastic fibre formation) were also supported across analyses (in Tables 4.3 and D.3) consistent with the

established cell-cell signalling role of *CDH1* and the importance of the tumour microenvironment for cancer proliferation.

4.2 Comparison of synthetic lethal gene candidates

4.2.1 Comparison with siRNA screen candidates

Gene candidates were compared between computational (SLIPT in TCGA breast cancer data) and experimental (the primary siRNA screen performed by Telford *et al.* (2015)) approaches in Figure 4.2. The number of genes detected by both methods did not produce a significant overlap but these may be difficult to compare due to vast differences between the detection methods. There were similar issues comparison of mtSLIPT genes tested against *CDH1* mutations (in Figure G.2), despite excluded genes not tested by both methods in either test. However, these intersecting genes may still be functionally informative or amenable to drug triage as they were replicated across both methods and pathway over-representation differed between the sections of the Venn diagram (see Figure 4.2).



4.2.1.1 Comparison with correlation




Figure 4.3: **Compare SLIPT and siRNA genes with correlation.** The χ^2 p-values for genes tested by SLIPT (in TCGA breast cancer) expression analysis were compared against Pearson's correlation of gene expression with *CDH1*. Genes detected by SLIPT or siRNA are coloured according to the legend.




Figure 4.4: **Compare SLIPT and siRNA genes with correlation.** Genes detected as candidate synthetic lethal partners by SLIPT (in TCGA breast cancer) expression analysis and experimental screening (with siRNA) were compared against Pearson's correlation of gene expression with *CDH1*. There were no differences in correlation between gene groups detected by either approach.

Another potential means to triage drug target candidates is correlation of expression profiles with *CDH1*. Correlation with *CDH1* was compared to SLIPT and siRNA results in Figure 4.3. The genes not detected by SLIPT (including siRNA candidates) included genes with high (insignificant) SLIPT p-values. As expected, these genes were distributed around a correlation of zero and genes with higher correlation with *CDH1* (either direction) had more significant SLIPT p-values, although there were exceptions to this trend and larger positive correlations were negative correlations.

The majority of SLIPT candidates appeared to have negative correlations and moreover for those genes detected by both approaches, although these were typically weak correlations and are unlikely to be sufficient to detect such genes on their own. This is supported by simulation results in Section ??.

There were not strong positive correlations with *CDH1* among siRNA candidates, consistent with previous findings that co-expression is not predictive of synthetic lethality (Jerby-Arnon *et al.*, 2014; Lu *et al.*, 2015). Negative correlation may not be indicative of synthetic lethality either as many siRNA candidates also had positive correlations. The SLIPT methodology has shown to detect genes with both positive and negative correlations, although it does appear to preferentially detect negatively correlated genes to some extent. These findings were replicated with the mtSLIPT approach against *CDH1* mutation (in Figure D.3), although the range of the χ^2 p-values differ due to lower sample size for mutation analysis.

However, the apparent tendency for genes detected by SLIPT or siRNA to have negative correlations with *CDH1* expression may be due to the smaller number of genes in these groups. The distribution of *CDH1* correlations does not differ across these gene groups (as shown by Figures 4.4 and D.4). Therefore further triage of gene candidates by correlation is not suitable, nor is use of correlation itself to predict synthetic lethal partners in the first place.

4.2.1.2 Comparison with viability

A similar comparison of SLIPT results was made with the viability ratio (of *CDH1* mutant to wildtype) in the primary siRNA screen performed by Telford *et al.* (2015). The significance and viability thresholds used for SLIPT and siRNA detection of synthetic lethal candidate partners of *CDH1* are clear in Figure 4.5. However note that not all of the genes below these thresholds are necessarily selected to be candidate partners as additional criteria were used in each case: directional criteria as for SLIPT (see Section 3.1) and minimum wildtype viability for siRNA (Telford *et al.*, 2015).




Figure 4.5: **Compare SLIPT and siRNA genes with siRNA viability.** The χ^2 p-values for genes tested by SLIPT (in TCGA breast cancer) expression analysis were compared against the viability ratio of *CDH1* mutant and wildtype cells in the primary siRNA screen. Genes detected by SLIPT or siRNA are coloured according to the legend.




Figure 4.6: **Compare SLIPT and siRNA genes with viability.** The χ^2 p-values for genes tested by SLIPT (in TCGA breast cancer) expression analysis were compared (on a log-scale) against the viability ratio of *CDH1* mutant and wildtype cells in the primary siRNA screen. Genes detected by SLIPT or siRNA are coloured according to the legend with a grey line for $p = 0.05$.

There does not appear to be a clear relationship between SLIPT and siRNA candidates. Many genes not detected by both approaches were numerous in Figures 4.2 and D.2. These genes detected by either are not necessarily near the thresholds for the other. In this respect the SLIPT approach with patient data and cell line experiments are independent means to identify synthetic lethal candidates. While genes detected by both approaches were not necessarily more strongly supported by either, the genes with a viability closer to 1 (no synthetic lethal effect) in siRNA included those with more significant SLIPT p-values whereas more extreme viability ratios tended to be less significant (as shown by a logarithmic plot in Figure 4.6). Although it should be noted that genes with more moderate viability ratios were more common and SLIPT was capable (despite adjusting for multiple testing) of detecting significant genes with extreme viability ratios, particularly those considerably lower than 1.

However, there was not support for SLIPT candidates or those detected by both approaches having considerably different viability ratios (as shown in Figures 4.7 and D.5). The difference between the gene groups stems largely from the viability thresholds used by Telford *et al.* (2015) to detect synthetic lethal candidates in the primary screen, rather than more extreme viability ratios for genes identified by SLIPT.




Figure 4.7: **Compare SLIPT and siRNA genes with siRNA viability.** Genes detected as candidate synthetic lethal partners by SLIPT (in TCGA breast cancer) expression analysis and experimental screening (with siRNA) were compared against the viability ratio of *CDH1* mutant and wildtype cells in the primary siRNA screen. There were clear no differences in viability between genes detected by SLIPT and those not with the differences being primarily due to viability thresholds being used to detect synthetic lethality by Telford *et al.* (2015).

4.2.1.3 Comparison with secondary siRNA screen candidates

However, it should be noted that genes with a lower viability ratio were not necessarily the strongest supported by experimental screening. The primary screen (with 4 pooled siRNAs) has been used for the majority of comparisons in this thesis because the genome-wide panel of target genes screened enables a large number of genes to be compared with SLIPT results from gene expression and somatic mutation analysis. A secondary screen was also performed by Telford *et al.* (2015) on the isogenic MCF10A breast cell lines to individually validate the siRNAs separately, with the strongest candidates being those exhibiting synthetic lethal viability ratios replicated across independently targeting siRNAs. This was performed for the top 500 candidates (with the lowest viability ratio) from the primary screen and the 482 of these genes also tested by SLIPT in breast cancer (and the 486 genes tested by SLIPT in stomach cancer).

The secondary screen results are given in Appendix C which show that SLIPT candidate genes are more significantly ($p = 7.49 \times 10^{-3}$ by Fisher's exact test) more likely to be validated in the secondary screen and are thus informative of more robust partner genes, in addition to providing support that these interactions are consistent with expression profiles from heterogeneous patient samples across genetic backgrounds. While the individual genes detected by either approach do not necessarily match (and are potentially false-positives), the biological functions important in *CDH1* deficient cancers and potential mechanisms for specific targeting of them can be further supported by pathway analysis of the gene detected by either method. The genes detected by both approaches may therefore be more informative at the pathway level, where it is unlikely for a pathway to be consistently detected by chance. As the SLIPT candidates differ from the siRNA candidates (and are more likely to be validated), they can provide additional mechanisms by which *CDH1* deficient cancers proliferate and vulnerabilities that may be exploited against them by using the synthetic lethal pathways.

4.2.1.4 Comparison of screen at pathway level

These pathway over-representation analyses (performed as described in Section 2.3.2) correspond to genes separated into SLIPT or siRNA screen candidates unique to either method or detected by both (Table 4.4). The SLIPT-specific gene candidates were involved most strongly with translational and immune regulatory pathways, although extracellular matrix pathways were also supported. These pathways were largely consistent with those identified in Table 4.2 and in the clustering analysis (Table 4.3). The

Table 4.4: Pathway composition for *CDH1* partners from SLIPT and siRNA screening

Predicted only by SLIPT (4025 genes)	Pathway Size	Genes Identified	p-value (FDR)
Eukaryotic Translation Elongation	80	75	1.5×10^{-182}
Peptide chain elongation	77	72	2.9×10^{-176}
Viral mRNA Translation	75	70	4.9×10^{-172}
Eukaryotic Translation Termination	76	70	5.9×10^{-170}
Formation of a pool of free 40S subunits	87	74	9.5×10^{-166}
Nonsense Mediated Decay independent of the Exon Junction Complex	81	70	1.2×10^{-160}
L13a-mediated translational silencing of Ceruloplasmin expression	97	75	3.8×10^{-155}
3' -UTR-mediated translational regulation	97	75	3.8×10^{-155}
GTP hydrolysis and joining of the 60S ribosomal subunit	98	75	6.0×10^{-154}
Nonsense-Mediated Decay	96	73	5.2×10^{-150}
Nonsense Mediated Decay enhanced by the Exon Junction Complex	96	73	5.2×10^{-150}
SRP-dependent cotranslational protein targeting to membrane	97	73	7.8×10^{-149}
Eukaryotic Translation Initiation	105	75	4.7×10^{-146}
Cap-dependent Translation Initiation	105	75	4.7×10^{-146}
Translation	133	83	4.0×10^{-142}
Influenza Viral RNA Transcription and Replication	102	71	2.9×10^{-137}
Influenza Infection	111	74	3.7×10^{-137}
Influenza Life Cycle	106	71	2.3×10^{-133}
Infectious disease	326	125	4.2×10^{-120}
Extracellular matrix organisation	189	77	5.4×10^{-95}

Detected only by siRNA screen (1599 genes)	Pathway Size	Genes Identified	p-value (FDR)
Class A/1 (Rhodopsin-like receptors)	282	44	1.3×10^{-27}
GPCR ligand binding	363	52	5.8×10^{-26}
G _{αs} signalling events	159	26	6.7×10^{-23}
Gastrin-CREB signalling pathway via PKC and MAPK	180	27	2.0×10^{-21}
G _{αi} signalling events	184	27	5.3×10^{-21}
Downstream signal transduction	146	23	7.6×10^{-21}
Signalling by PDGF	172	25	4.0×10^{-20}
Peptide ligand-binding receptors	175	25	8.5×10^{-20}
Signalling by ERBB2	146	22	1.3×10^{-19}
DAP12 interactions	159	23	2.6×10^{-19}
DAP12 signalling	149	22	2.7×10^{-19}
Organelle biogenesis and maintenance	264	33	5.5×10^{-19}
Signalling by NGF	266	33	8.2×10^{-19}
Downstream signalling of activated FGFR1	134	20	1.1×10^{-18}
Downstream signalling of activated FGFR2	134	20	1.1×10^{-18}
Downstream signalling of activated FGFR3	134	20	1.1×10^{-18}
Downstream signalling of activated FGFR4	134	20	1.1×10^{-18}
Signalling by FGFR	146	21	1.3×10^{-18}
Signalling by FGFR1	146	21	1.3×10^{-18}
Signalling by FGFR2	146	21	1.3×10^{-18}

Intersection of SLIPT and siRNA screen (604 genes)	Pathway Size	Genes Identified	p-value (FDR)
Visual phototransduction	54	9	6.9×10^{-10}
G _{αs} signalling events	48	7	1.6×10^{-7}
Retinoid metabolism and transport	24	5	1.7×10^{-7}
Acyl chain remodelling of PS	10	3	6.5×10^{-6}
Transcriptional regulation of white adipocyte differentiation	51	6	6.5×10^{-6}
Chemokine receptors bind chemokines	22	4	6.5×10^{-6}
Signalling by NOTCH4	11	3	6.9×10^{-6}
Defective EXT2 causes exostoses 2	11	3	6.9×10^{-6}
Defective EXT1 causes exostoses 1, TRPS2 and CHDS	11	3	6.9×10^{-6}
Platelet activation, signalling and aggregation	146	12	6.9×10^{-6}
Phase 1 - Functionalisation of compounds	41	5	1.3×10^{-5}
Amine ligand-binding receptors	13	3	1.7×10^{-5}
Acyl chain remodelling of PE	14	3	2.4×10^{-5}
Signalling by GPCR	300	23	2.4×10^{-5}
Molecules associated with elastic fibres	29	4	2.6×10^{-5}
DAP12 interactions	128	10	2.6×10^{-5}
Cytochrome P ₄₅₀ - arranged by substrate type	30	4	3.2×10^{-5}
GPCR ligand binding	147	11	3.8×10^{-5}
Acyl chain remodelling of PC	16	3	4.0×10^{-5}
Response to elevated platelet cytosolic Ca ²⁺	66	6	4.2×10^{-5}

genes detected only by the siRNA screen had over-representation of cell signalling pathways, including many containing genes known to be involved in cancer (e.g., MAPK, PDGF, ERBB2, and FGFR), with the detection of Class A GPCRs supporting the independent analyses by Telford *et al.* Telford *et al.* (2015). The intersection of computational and experimental synthetic lethal partners of *CDH1* has stronger evidence for over-representation of GPCR pathways and more specific subclasses, such as visual phototransduction ($p = 6.9 \times 10^{-10}$) and $G_{\alpha s}$ signalling events ($p = 1.7 \times 10^{-7}$), than other signalling pathways.

The pathway analysis for mtSLIPT against *CDH1* mutations (in Table D.4) had concordant results for both mtSLIPT-specific and siRNA-specific pathways. While the specific pathway composition of the intersection of these analyses differed from SLIPT against low *CDH1* expression, signalling pathways including GPCRs, NOTCH, EERB2, PDGF, and SCF-KIT. These findings indicate the signalling pathways are among the most suitable vulnerability to exploit in targeting *CDH1* deficient tumours as they can be detected in both a patient cohort (with TCGA expression data) and tested in a laboratory system. However, it is possible that the isolated experimental system is set up to preferentially detect kinase signalling pathways (which are amenable to pharmacological inhibition and translation to the clinic) and the other pathways identified by SLIPT may still be informative of the role of *CDH1* loss of function in cancers or mechanisms by which further gene loss leads to specific inviability.

4.2.1.4.1 Resampling of genes for pathway enrichment

Comparing genes between experimental screen candidates and prediction from TCGA expression data has been less consistent than pathways. Although this is not unexpected since synthetic lethal pathways more more robustly conserved (Dixon *et al.*, 2008) and the computational approach using patient samples from complex tumour microenvironment has considerably different strengths to an experimental screen (Telford *et al.*, 2015) based on genetically homogenous cell line models in an isolated laboratory environment. For instance, it is unlikely for immune signaling to be detected in an isolated cell culture system.

The overlap between synthetic lethal from bioinformatics SLIPT predictions and siRNA screening has raised other questions including whether the pathways over-represented would be expected by chance. This of particular concern since the siRNA candidate genes themselves are highly over-represented for particular pathways (such as GPCRs) so selecting any intersect with them would be enriched for these pathways.




Figure 4.8: **Resampled intersection of SLIPT and siRNA candidates.** Re-sampling analysis of intersect size from genes detected by SLIPT and siRNA screening approaches over 1 million replicates. The proportion of expected intersection sizes for random samples below or above the observed intersection size respectively, lacking significant over-representation or depletion of siRNA screen candidates within the SLIPT predictions for *CDH1*.

Another pathway approach is to test whether pathways are over-represented in randomly sampled genes, comparing many “resamplings” or “permutations” of these genes to the enrichment statistics observed for these pathways in the SLIPT candidates and their intersection with the siRNA hits shows whether we detect these pathways more than we expect by chance (as described in Section 2.3.6).

Of particular concern are the over-represented pathways in genes detected by both methods. Pathway over-representation alone does not detect whether SLIPT predicted genes or siRNA candidates are enriched within each other. This resampling analysis therefore detects whether over-represented pathways were detected by SLIPT independently of their over-representation among siRNA candidates (without assuming an underlying test statistic distribution).

A resampling approach is also applicable to testing whether the number of genes detected by each approach significantly intersected. As shown in Figure 4.8, resampling did not find evidence of significant depletion or over-representation for experimental synthetic lethal candidates in the computationally predicted synthetic lethal partners of *CDH1* and the overlap may be observed by chance. This is consistent with previous

findings (see Figure 4.2) and does not preclude pathway relationships being supported by resampling.

A permutation analysis was performed to resample the genes tested by both approaches to investigate whether the observed pathway over-representation could have occurred in a randomly selected sample of genes from the experimental candidates, that is, whether the pathway predictions from SLIPT could be expected by chance (as described in sections 2.2.3.1 and 2.3.6). While the number of siRNA candidate genes detected by SLIPT was not statistically significant ($p = 0.281$), this may be due to the vastly different limitations of the approaches and the correlation structure of gene expression not being independent (as assumed for multiple testing procedures). The intersection may still be functionally relevant to *CDH1*-deficient cancers, such as the pathway data in Table 4.4. The resampling analysis for pathways was compared to the pathway over-representation for SLIPT predicted synthetic lethal partners in Table 4.5. Similarly, the pathway resampling for intersection between SLIPT predictions and experimental screen candidates was compared to pathway over-representation in Table 4.6 for intersection with siRNA data.

The pathway resampling approach for SLIPT-specific gene candidates (Table 4.5) replicates the gene set over-representation analysis for all SLIPT genes, detecting evidence of synthetic lethal pathways for *CDH1* in translational, immune, and cell signalling pathways including $G_{\alpha i}$ signalling, GPCR downstream signalling, and chemokine receptor binding. While the immune and signal transduction pathways were not significantly over-represented in the resampling analysis, the results for the two approaches were largely consistent for translation and post-transcriptional gene regulation, supporting gene set over-representation of the SLIPT-specific pathways in Table 4.5. In particular, some of the most significantly over-represented pathways had higher observed χ^2 values than any of the 1 million random permutations. Similar pathways were also replicated by permutation analysis for mtSLIPT candidate partners against *CDH1* mutation (shown in Table D.5). This shows that many of the pathways detected specifically by SLIPT are replicated by permutation procedures and that the permutation approach is capable of detecting many of the most strongly over-represented pathways.

The permutation approach was then also applied to the intersection between computational and experimental candidates. Where the permutation analysis is testing for consistent detection of pathways independent of their pre-existing status as exper-

Table 4.5: Pathways for *CDH1* partners from SLIPT

Reactome Pathway	Over-representation	Permutation
Eukaryotic Translation Elongation	1.3×10^{-207}	$< 1.241 \times 10^{-5}$
Peptide chain elongation	5.6×10^{-201}	$< 1.241 \times 10^{-5}$
Viral mRNA Translation	1.2×10^{-196}	$< 1.241 \times 10^{-5}$
Eukaryotic Translation Termination	1.2×10^{-196}	$< 1.241 \times 10^{-5}$
Formation of a pool of free 40S subunits	3.7×10^{-194}	$< 1.241 \times 10^{-5}$
Nonsense Mediated Decay independent of the Exon Junction Complex	5.3×10^{-187}	$< 1.241 \times 10^{-5}$
L13a-mediated translational silencing of Ceruloplasmin expression	9.6×10^{-183}	$< 1.241 \times 10^{-5}$
3' -UTR-mediated translational regulation	9.6×10^{-183}	$< 1.241 \times 10^{-5}$
GTP hydrolysis and joining of the 60S ribosomal subunit	1.9×10^{-181}	$< 1.241 \times 10^{-5}$
Nonsense-Mediated Decay	6.2×10^{-176}	$< 1.241 \times 10^{-5}$
Nonsense Mediated Decay enhanced by the Exon Junction Complex	6.2×10^{-176}	$< 1.241 \times 10^{-5}$
Adaptive Immune System	6.5×10^{-174}	0.15753
Eukaryotic Translation Initiation	5.7×10^{-173}	$< 1.241 \times 10^{-5}$
Cap-dependent Translation Initiation	5.7×10^{-173}	$< 1.241 \times 10^{-5}$
SRP-dependent cotranslational protein targeting to membrane	2.0×10^{-171}	$< 1.241 \times 10^{-5}$
Translation	6.1×10^{-170}	$< 1.241 \times 10^{-5}$
Infectious disease	1.6×10^{-166}	0.23231
Influenza Infection	1.9×10^{-163}	$< 1.241 \times 10^{-5}$
Influenza Viral RNA Transcription and Replication	1.9×10^{-160}	$< 1.241 \times 10^{-5}$
Influenza Life Cycle	2.5×10^{-156}	$< 1.241 \times 10^{-5}$
<i>Extracellular matrix organisation</i>	1.1×10^{-152}	0.071761
GPCR ligand binding	1.1×10^{-143}	0.55801
Class A/1 (Rhodopsin-like receptors)	1.5×10^{-142}	0.58901
<i>GPCR downstream signalling</i>	7.6×10^{-140}	0.098357
Haemostasis	1.9×10^{-134}	0.27059
Developmental Biology	2.0×10^{-123}	0.52737
Metabolism of lipids and lipoproteins	3.3×10^{-120}	0.724
Cytokine Signalling in Immune system	2.6×10^{-119}	0.39661
Peptide ligand-binding receptors	3.7×10^{-109}	0.61102
G$_{\alpha s}$ signalling events	8.9×10^{-100}	$< 1.241 \times 10^{-5}$

Over-representation (hypergeometric test) and Permutation p-values adjusted for multiple tests across pathways (FDR). Significant pathways are marked in bold (FDR < 0.05) and italics (FDR < 0.1).

imental candidates. The pathway results for these candidate partners (in Table 4.6) differed between over-representation and resampling analyses.

Namely, many of the over-represented pathways were not significant in the re-sampling analysis, including visual phototransduction and retinoic acid signalling, although pathways involving defective *EXT1* or *EXT2* genes approach significance after FDR adjustment for multiple tests. Of the highest over-represented pathways in the intersection, only G $_{\alpha s}$ signalling events were supported by both over-representation and resampling analyses. Other pathways supported by both analyses were cytoplasmic elastic fibre formation, associated HS-GAG protein modification pathways, energy metabolism, and the fibrin clotting cascade.

Many of the pathways supported in the intersection by permutation analysis were also replicated in the mtSLIPT analysis of partners tested with *CDH1* mutation (in Table D.6), including G $_{\alpha s}$, elastic fibres, HS-GAG, and energy metabolism. While there were differences between the pathways Identified by over-representation analysis,

Table 4.6: Pathways for *CDH1* partners from SLIPT and siRNA primary screen

Reactome Pathway	Over-representation	Permutation
Visual phototransduction	6.9×10^{-10}	0.91116
G_{as} signalling events	1.6×10^{-7}	0.012988
Retinoid metabolism and transport	1.7×10^{-7}	0.20487
Transcriptional regulation of white adipocyte differentiation	6.5×10^{-6}	0.38197
Acyl chain remodelling of PS	6.5×10^{-6}	0.58485
Chemokine receptors bind chemokines	6.5×10^{-6}	0.97255
<i>Defective EXT2 causes exostoses 2</i>	6.9×10^{-6}	0.056437
<i>Defective EXT1 causes exostoses 1, TRPS2 and CHDS</i>	6.9×10^{-6}	0.056437
Signalling by NOTCH4	6.9×10^{-6}	0.15497
Platelet activation, signalling and aggregation	6.9×10^{-6}	0.53358
Phase 1 - Functionalisation of compounds	1.3×10^{-5}	0.24836
Amine ligand-binding receptors	1.7×10^{-5}	0.3195
Acyl chain remodelling of PE	2.4×10^{-5}	0.7307
Signalling by GPCR	2.4×10^{-5}	0.9939
Molecules associated with elastic fibres	2.6×10^{-5}	0.0072929
DAP12 interactions	2.6×10^{-5}	0.78273
Cytochrome P ₄₅₀ - arranged by substrate type	3.2×10^{-5}	0.87019
GPCR ligand binding	3.8×10^{-5}	0.99417
Acyl chain remodelling of PC	4.0×10^{-5}	0.65415
Response to elevated platelet cytosolic Ca ²⁺	4.2×10^{-5}	0.55461
<i>Arachidonic acid metabolism</i>	4.4×10^{-5}	0.060298
Defective B4GALT7 causes EDS, progeroid type	4.9×10^{-5}	0.15497
Defective B3GAT3 causes JDSSDHD	4.9×10^{-5}	0.15497
Elastic fibre formation	4.9×10^{-5}	0.0019227
HS-GAG degradation	6.2×10^{-5}	0.017747
Bile acid and bile salt metabolism	6.2×10^{-5}	0.15497
Netrin-1 signalling	7.1×10^{-5}	0.95056
Integration of energy metabolism	7.1×10^{-5}	0.0019287
DAP12 signalling	7.9×10^{-5}	0.67835
GPCR downstream signalling	8.1×10^{-5}	0.88678
Diseases associated with glycosaminoglycan metabolism	8.7×10^{-5}	0.017747
Diseases of glycosylation	8.7×10^{-5}	0.017747
Signalling by Retinoic Acid	8.7×10^{-5}	0.13592
Signalling by Leptin	8.7×10^{-5}	0.15497
Signalling by SCF-KIT	8.7×10^{-5}	0.73399
Opioid Signalling	8.7×10^{-5}	0.99417
Signalling by NOTCH	0.0001	0.26453
Platelet homeostasis	0.0001	0.55912
Signalling by NOTCH1	0.00011	0.13797
Class B/2 (Secretin family receptors)	0.00011	0.4659
Diseases of Immune System	0.00013	0.15497
Diseases associated with the TLR signalling cascade	0.00013	0.15497
A tetrasaccharide linker sequence is required for GAG synthesis	0.00013	0.33566
Nuclear Receptor transcription pathway	0.00016	0.22735
Formation of Fibrin Clot (Clotting Cascade)	0.00016	0.0054639
Syndecan interactions	0.00016	0.3974
Class A/1 (Rhodopsin-like receptors)	0.00016	0.99454
HS-GAG biosynthesis	0.0002	0.37199
Platelet degranulation	0.0002	0.39003
EPH-ephrin mediated repulsion of cells	0.00021	0.6193

Over-representation (hypergeometric test) and Permutation p-values adjusted for multiple tests across pathways (FDR). Significant pathways are marked in bold (FDR < 0.05) and italics (FDR < 0.1).

those replicated by permutation were highly concordant supported the combined use of these pathways approaches to identify synthetic lethal gene functions and targets.

While this indicates that $G_{\alpha s}$ and GPCR class A/1 signalling events were significantly detected by both approaches, GPCR signalling pathways overall were not. It is likely that GPCRs were primarily over-represented in the intersection with the experimental candidates due to strong over-representation of these pathways in experimental candidates, rather than detection by SLIPT, which may be driven by these more specific constituent pathways.

However, several pathways, including some immune functions and neurotransmitters, were supported by the resampling analysis (in Tables 4.6 and D.6) when the initial pathway over-representation test was not significant. These functions appear to have been detected by both approaches more than expected by chance but must be interpreted with caution since they were still not common enough to be detected in pathway over-representation analysis.

Therefore computational and experimental approaches to synthetic lethal screening for *CDH1* lead to a broader functional characterisation and many candidate partners, when combined, despite different strengths and limitations. Compared to candidate gene approaches, experimental genome-wide screens are an appealing unbiased strategy for identifying synthetic lethal interactions. Since these screens are costly, laborious, and subject to genetic background, computational analysis can augment candidate triage to either reduce the initial panel of screened genes or prioritise validation.

GPCR pathways were detected among both computational and experimental synthetic lethal candidates, with more support in the experimental screen (Table 4.6). The homogeneous cell line model may be more likely to detect particular pathways. For instance, SLIPT identified immune pathways, not expected to be detected in isolated cell culture. GPCR signalling was supported in experimental models Telford *et al.* (2015) with some of these pathways replicated in varied genetic backgrounds of patient samples. These pathways require further investigation such as identification of more specific pathways, higher order interactions, and modes of resistance.

The pathway composition across computational and experimental synthetic lethal candidates was informative with over-representation (Table 4.4) and supported by resampling analysis (Table 4.6), despite a modest intersection of genes between them (Figure 4.2). Either approach may be significant for a pathway in this intersection without being supported by the other: resampling analysis may support pathways that were not over-represented due to small effect sizes, thus both tests are required

for a candidate pathway. The pathways detected by both over-representation and re-sampling are the strongest candidates for further investigation, such as $G_{\alpha s}$ signalling, a strong candidate in prior analyses with a role in the regulation of translation in cancer Gao and Roux (2015), another function supported by SLIPT analysis.


The predicted synthetic lethal partners occurred across functionally distinct pathways, including characterised functions of *CDH1*. This diversity is consistent with the wide ranging role of *CDH1* in cell-cell adhesion, cell signalling, and the cytoskeletal structure of epithelial tissues. Pathway structure may be relevant to identifying potential drug targets from gene expression signatures, indicating downstream effector genes and mechanisms leading to cell inviability. These distinct synthetic lethal gene clusters and pathways may further lead to the elucidation of drug resistance mechanisms.

4.3 Metagene Analysis

Metagenes serve as a consistent signal of pathway activity. The direction of metagenes is generally arbitrary but care has been taken to ensure that these occur in a direction which reflect overall activation of the pathway (as described in Section 2.2.3). This will be supported by examining the pathway expression of gene signatures in breast cancer to ensure they behave as expected in TCGA expression data. These metagenes were also compared to somatic mutation to show the limitations of mutation as a measure of gene activity. Having established that metagenes generated with this procedure reflect gene activity, these were then applied to the Reactome pathways for synthetic lethal analysis of pathways directly to provide an alternative approach to identifying synthetic lethal pathways with *CDH1*.

4.3.1 Pathway expression


Pathway metagenes (generated as described in Section 2.2.3) for gene signatures of key processes in breast cancer (Gatza *et al.*, 2011) were used to check that metagenes were generated in the correct direction to indicate pathway activation. These gene signatures were plotting in Figure 4.9 for comparison with clinical factors and somatic mutations. The “intrinsic subtype” was computed by performing the PAM50 procedure Parker *et al.* (2009) for RNASeq data which was highly concordant with the subtypes provided by UCSC for TCGA samples previously analysed by microarrays (TCGA, 2012). Somatic mutations were reported for recurrently mutated genes in breast cancer, as reported by TCGA (TCGA, 2012), related genes, and those previously discussed to be important in hereditary breast cancers (*BRCA1*, *BRCA2*, and *CDH1*).




These gene signatures reflect intrinsic subtypes as expected. In particular, the estrogen and progesterone receptor signatures are low in the ER– and PR– basal subtype tumours. These tumours also had the highest frequency of *TP53* mutations and a corresponding reduction of p53 metagene activity, as expected for loss of a tumour suppressor. The luminal A and luminal B tumour subtypes are the most similar, which is reflected in these metagenes signatures, although they are distinguishable molecular subtypes as shown by elevated PI3K, AKT, RAS, and β -catenin signalling in luminal B tumours. Although, these pathways were also elevated in Basal and HER2-enriched subtypes and lowly expressed in the “normal-like” subtype (which contained the normal samples). These intrinsic subtype specific gene signature profiles were further supported with metagenes for an extended set of signatures (Gatza *et al.*, 2014), as shown in Figure E.1.

TP53 mutations were the most frequent and more common in basal subtype. Similarly, *GATA3* mutations were more common in luminal subtype tumours. PI3K mutations were more frequent across breast tumours, although these were less common in the basal subtype despite an elevated metagene (this discrepancy will be discussed further in Section 4.3.2). *CDH1* mutations similarly occurred across molecular subtypes with the exception of the basal subtype (as observed in gene expression with Figure 4.1). *CDH1* low samples occurred in all subtypes but were predominantly lobular subtype. Apart from these genes, mutations did not show clear specificity to a particular subtype and the variation between samples reflects the range of molecular cascades that can result in tumours with similar molecular profiles, supporting the use of expression for cancer diagnostics and identification of molecular targets.


The direction of the metagenes were also consistent with the clinical characteristics and formed a consensus of gene activity as shown in Figures E.2–E.5. In each of the examples for gene signatures for PI3K (Figure E.2), p53 (Figure E.3), estrogen receptor (Figure E.4), and BRCA (Figure E.5) genes (Gatza *et al.*, 2011, 2014), the expression of the majority of the genes were highly concordant with the metagene, being either positively or negatively correlated. These were generally consistent with established clinical and molecular subtypes of breast cancer and the recurrent mutations shown. However, the *PIK3CA* and *PIK3R1* mutant samples did not necessarily have elevated PI3K pathway metagene activity (as shown in Figure E.2).




(a) *PIK3CA* mutation



(b) *PIK3CA* or *PIK3R1* mutation



(c) *CDH1* mutation



(d) *TP53* mutation

Figure 4.10: **Somatic mutation against PI3K metagene.** Mutations in *PIK3CA*, *PIK3R1*, *CDH1*, and *TP53* were examined in TCGA breast cancer for their effect on the PI3K (Gatza *et al.*, 2011) pathway metagene. The tumour suppressors *CDH1* and *TP53* showed an increase and decrease in the metagene respectively, whereas *PIK3CA* and *PIK3R1* mutations had little effect on the metagene levels.

4.3.2 Somatic mutation

It should be noted that metagenes, while consistent with the consensus of constituent expressed genes, were not necessarily reflecting the somatic mutation status. The PI3K (Gatza *et al.*, 2011) metagene levels in particular, were not statistically sig-


nificant in between mutant and wildtype *PIK3CA* samples (shown in Figure 4.10). Although the PI3K metagene differed across *CDH1* and *TP53* mutations, remarkably in opposite directions considering that PI3K is an oncogenic growth pathway and these are both most frequently tumour suppressors inactivated in cancers. This shows that *CDH1* and *TP53* deficient tumours have distinct molecular growth pathways and that synthetic lethal inactivations against *CDH1* inactivation may not be applicable to other cancers with driver mutations such as *TP53*, although these were kept in the analysis for comparison. These differences may be related to these mutations being more frequent in tumours with difference clinical characteristics (as observed in Section 4.3.1). Thus mutations do not necessarily have corresponding changes in pathway expression, particularly for oncogenes which may change in function rather than being upregulated.

While the more specific *PIK3CA* (Gatza *et al.*, 2014) metagene showed significant differences with *PIK3CA* and *PIK3R1* mutations (as shown in Figure D.7), this metagene replicated stronger differences for *CDH1* and *TP53*. These differences were less pronounced in the protein levels of p110 α (encoded by *PIK3CA*) and the downstream AKT gene (shown in Figures D.8 and D.9 respectively). Although this may be due to this regulatory cascade (kinases) being transmitted as a change in protein state (phosphorylation) rather than changes in expression levels. Another consideration is that mutations at different loci have different effects on protein function, particularly for oncogenes.

4.3.3 Mutation locus

The gene locus distribution of *PIK3CA* and its receptor *PIK3R1* were consistent with oncogenic and tumour suppressor mutations, as shown in Figure D.6. *PIK3CA* has recurrent mutations in 2 hotspots, centered around the E545K and H1047R (shown in Figure D.6a), as expected for an oncogene. This contrasts with the tumour suppressors, *PIK3R1*, and *CDH1* (shown in Figures D.6b and D.6c respectively), which have low frequency inactivating mutations spread across them. A notable exception is *TP53* (shown in Figure D.6d) which displays both inactivating mutations throughout and recurrent (oncogenic) mutations at high frequency, consistent with the complex role of *TP53* in cancer biology which is outside of the scope of this thesis and shown for comparison.


These differences in gene locus may explain why mutations do not necessarily have corresponding changes in gene or metagene expression. Specifically, the recurrent




(a) *PIK3CA* gene

(b) *PIK3CA* metagene


(c) *PIK3R1* gene




(d) *PIK3CA* protein



(e) *AKT* protein



(f) *CDH1* protein



(g) *TP53* protein

Figure 4.11: Somatic mutation locus against expression. The recurrent E545K and H1047R oncogene mutations in *PIK3CA* were examined in TCGA breast cancer to show the effect of mutation locus on gene, pathway, and protein expression. While neither of these mutations had an impact of *PIK3CA* mRNA expression, E545K had specifically lower PI3K (Gatza *et al.*, 2011) metagene levels and both mutations had higher *PIK3R1* mRNA expression. However, these differences were not reflected in the protein expression levels.

E545K and H1047R oncogene mutations in *PIK3CA* did not affect *PIK3CA* mRNA expression but E545K had specifically lower PI3K (Gatza *et al.*, 2011) metagene levels.

Both mutations had higher *PIK3R1* mRNA expression but these differences differences were not reflected in the protein expression levels of p110 α protein (encoded by *PIK3CA*), it's downstream target AKT, E-cadherin (encoded by *CDH1*), or p53 (as shown in Figure 4.11).

While the complex effects of mutation in oncogenes such as *PIK3CA* are not necessarily detected in a pathway metagene, these do capture the consensus of pathway gene expression and account for other potential means of pathway activation. Thus metagenes are sufficient as a measure of gene activity for the purposes of synthetic lethal detection with SLIPT. This approach is more applicable to tumour suppressor genes with a relationship between gene expression and activity (rather than activation at the protein level) but this is not a major concern since synthetic lethality is more clinically relevant for targeting tumour suppressor mutations than oncogenes.

4.3.4 Synthetic lethal metagenes

Pathway metagenes for Reactome pathways (generated as described in Section 2.2.3) were also used for testing synthetic lethal partner pathways with *CDH1* by SLIPT. Since the metagenes have are higher when the pathway as a whole is activated, they are amenable to SLIPT analysis using low metagene levels for inactivated pathways. These synthetic lethal metagenes differed to the over-represented pathways among synthetic lethal gene candidates. However, there were some similarities to previous findings, as shown in Tables 4.7. In particular, translational pathways were replicated as observed in Table 4.2. While the specific pathways differ, immune pathways (such as NF- κ B) were also supported by metagene synthetic lethal analysis.

Signalling pathways were more strongly supported by mtSLIPT analysis of metagene pathway expression against *CDH1* mutation, as shown in Table D.7. Although these results were generally less statistically significant than expression analyses. Signalling pathways detected as synthetic lethal metagenes include *G α z*, insulin-related growth factor (IGF), GABA receptor, *G α s*, S6K1 and various toxin responses mediated by GPCRs. Metabolic processes including processing of carbohydrates and fatty acids were also implicated across these analyses.

The metagene analyses differ more between expression and *CDH1* mutation than previous analyses, with more specific signalling pathways identified in the mutation analysis. This supports the usage of a complete null mutant model in experimental testing for synthetic lethality of signalling pathways against *CDH1* inactivation rather than a knockdown in expression. However, low expression of partners has been used in

Table 4.7: Candidate synthetic lethal metagenes against *CDH1* from SLIPT

Pathway	ID	Observed	Expected	χ^2 value	p-value	p-value (FDR)
Glycogen storage diseases	3229121	68	130	176	6.62×10^{-37}	1.82×10^{-34}
Myoclonic epilepsy of Lafora	3785653	68	130	176	6.62×10^{-37}	1.82×10^{-34}
Diseases of carbohydrate metabolism	5663084	68	130	176	6.62×10^{-37}	1.82×10^{-34}
Arachidonic acid metabolism	2142753	81	130	157	8.13×10^{-33}	1.49×10^{-30}
Translation initiation complex formation	72649	70	130	152	7.08×10^{-32}	1.17×10^{-29}
Synthesis of 5-eicosatetraenoic acids	2142688	68	130	151	1.25×10^{-31}	1.88×10^{-29}
SRP-dependent cotranslational protein targeting to membrane	1799339	69	130	150	2.01×10^{-31}	2.76×10^{-29}
L13a-mediated translational silencing of Ceruloplasmin expression	156827	72	130	148	5.91×10^{-31}	6.44×10^{-29}
3' -UTR-mediated translational regulation	157279	72	130	148	5.91×10^{-31}	6.44×10^{-29}
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S	72662	70	130	147	1.14×10^{-30}	9.28×10^{-29}
Formation of the ternary complex, and subsequently, the 43S complex	72695	70	130	147	1.14×10^{-30}	9.28×10^{-29}
Ribosomal scanning and start codon recognition	72702	70	130	147	1.14×10^{-30}	9.28×10^{-29}
Eukaryotic Translation Elongation	156842	72	130	146	1.19×10^{-30}	9.28×10^{-29}
Nonsense Mediated Decay independent of the Exon Junction Complex	975956	71	130	146	1.24×10^{-30}	9.28×10^{-29}
Viral mRNA Translation	192823	70	130	146	1.51×10^{-30}	1.04×10^{-28}
Eukaryotic Translation Termination	72764	70	130	146	1.51×10^{-30}	1.04×10^{-28}
NF-kB is activated and signals survival	209560	71	130	145	1.90×10^{-30}	1.19×10^{-28}
Peptide chain elongation	156902	72	130	145	1.91×10^{-30}	1.19×10^{-28}
Influenza Life Cycle	168255	70	130	145	1.95×10^{-30}	1.19×10^{-28}
Formation of a pool of free 40S subunits	72689	73	130	145	2.01×10^{-30}	1.19×10^{-28}
Nonsense-Mediated Decay	927802	71	130	145	2.44×10^{-30}	1.34×10^{-28}
Nonsense Mediated Decay enhanced by the Exon Junction Complex	975957	71	130	145	2.44×10^{-30}	1.34×10^{-28}
GTP hydrolysis and joining of the 60S ribosomal subunit	72706	72	130	145	2.58×10^{-30}	1.37×10^{-28}
Influenza Viral RNA Transcription and Replication	168273	72	130	144	4.01×10^{-30}	2.07×10^{-28}
Signaling by NOTCH1 HD Domain Mutants in Cancer	2691230	79	130	143	5.99×10^{-30}	2.82×10^{-28}

Strongest candidate SL partners for *CDH1* by SLIPT with observed and expected samples with low expression of both genes

either case to be applicable to dose-dependent pharmacological inhibition and across genes where mutations have different functional consequences, including variants of unknown significance.

These results show an independent pathway approach to detecting synthetic lethal gene functions interacting with *CDH1*. Synthetic lethal metagenes, replicates support for these pathways independent of pathway size (as genes are weighted equally). The synthetic lethal analysis against low *CDH1* expression support prior findings in translational and immune pathways even if they were not able to detected in an experimental screen (Telford *et al.*, 2015). Together these findings support the role of *CDH1* loss in cancer disrupting cell signalling with wider effects on protein translation and metabolism necessary for the proliferation of cancer cells. This is consistent with the GPCR pathways such as *G α s* signalling being supported by SLIPT gene candidates and the experimental primary siRNA screen, as shown by resampling in Section 4.2.1.4.1.

4.4 Replication in stomach cancer

The synthetic lethal analysis of genes and pathways (previously described for TCGA breast cancer data) was replicated in TCGA stomach cancer. The accompanying data

for SLIPT and mtSLIPT analyses against *CDH1* expression and mutation are in Appendices F and G respectively.

The experimental screen (Telford *et al.*, 2015) was conducted in MCF10A breast cells so it may not be as comparable to stomach cancer. Nevertheless, *CDH1* is also important in stomach cancer biology as a driver tumour suppressor gene and as a germline mutation in many cases of hereditary diffuse gastric cancer.

While the sample size was lower for TCGA stomach cancer (particularly for mutations), these results serve to support the findings in breast cancer in an independent patient cohort and tissue samples. The molecular profiling, including RNA-Seq expression, were performed by TCGA using the sample procedures as for breast cancer and the findings reported here were performed using data analysis techniques identical to those presented previously. These procedures should ensure as close comparison as feasible across cancer types for those relevant to HDGC and recurrent *CDH1* mutations.

4.4.1 Synthetic Lethal Genes and Pathways

The strongest SLIPT genes for stomach cancer (shown in Table F.1) did not necessarily directly correspond to those observed in breast cancer (shown in Table 4.1). However, several gene functions were replicated in stomach cancer. Cell membrane genes including *EMP3*, *GYPC*, *LGALS1*, *PRR24*, and *FUNCD2* were among the strongest SL candidates. Similarly, cell signalling genes including *PLEKHO1*, *RARRES2*, *VEGFB*, *HSPB2*, and *CREM* were detected in stomach cancers. It is notable that several of these genes (*EMP3*, *PLEKHO1*, and *FUNCD2*) have a known role in cancer. Together these genes support the roles of *CDH1* in cell membrane and signalling functions (of epithelial tissues) which are perturbed in both breast and stomach cancers.

The strongest mtSLIPT genes tested against *CDH1* mutation for stomach cancer (shown in Table G.1) supported similar gene functions. Membrane and cell-adhesion genes including *KFBP6*, *THY1*, *CLELC2B*, *NISCH*, *TSPAN1*, and *KCTD12* and signalling genes including *ZEB2*, *CCND2*, *NEURL1B*, *KFBP6*, and *OGN* were detected. Similarly, these include cancer genes such as *VIM*, *ZEB2*, *BCL2*, *THY1*, and *RUNX1T1*. The mtSLIPT procedure also replicated several of the strongest candidates in breast cancer (shown in Table D.1) such as *NRIP2* and *NISCH*.

Together, these gene candidates indicate widespread functions of *CDH1* and strongly detectable synthetic lethality with many genes from a strategy that can be applied across cancer types. More specifically, the signalling genes included GPCR signalling genes (such as *GNG11*, *GNAI1*, *DZIP1*, *PTGFR*, and *KCTD12*), a growth signalling

pathway which was one of the most supported synthetic lethal pathways in breast cancer analysis, the experimental screen (Telford *et al.*, 2015), and has many actionable drug targets which have been applied to other diseases.

These findings were further supported by the pathways over-represented in SLIPT candidates from TCGA stomach cancer (shown in Table 4.8) which were replicated the translational and immune pathways observed in TCGA breast cancer (shown in Tabel 4.2). Further support for GPCR signalling pathways including the class A/1 receptors. The extracellular matrix was also detected at the pathway level in stomach cancer SLIPT candidates and replicated in mtSLIPT analysis for *CDH1* mutation (shown in Table G.2), including elastic fibres, glycosylation, collagen, and integrin cell-surface interactions. Thus there was strong evidence for the role of extracellular matrix pathways and the tumour microenvironment in *CDH1* deficient stomach cancers, in addition to cell signalling and translation pathways important in tumour growth across breast and stomach cancer.

Table 4.8: Pathways for *CDH1* partners from SLIPT in stomach cancer

Pathways Over-represented	Pathway Size	SL Genes	p-value (FDR)
Extracellular matrix organization	241	104	7.5×10^{-140}
Hemostasis	445	138	1.8×10^{-121}
Developmental Biology	432	125	9.2×10^{-107}
Axon guidance	289	94	1.5×10^{-102}
Eukaryotic Translation Termination	84	49	1.9×10^{-99}
GPCR ligand binding	373	108	3.8×10^{-99}
Viral mRNA Translation	82	48	3.3×10^{-98}
Formation of a pool of free 40S subunits	94	51	3.3×10^{-98}
Eukaryotic Translation Elongation	87	49	1.6×10^{-97}
Peptide chain elongation	84	48	7.2×10^{-97}
Class A/1 (Rhodopsin-like receptors)	289	90	2.7×10^{-96}
Nonsense Mediated Decay independent of the Exon Junction Complex	89	49	3.0×10^{-96}
Infectious disease	349	100	2.6×10^{-94}
GTP hydrolysis and joining of the 60S ribosomal subunit	105	52	3.4×10^{-94}
L13a-mediated translational silencing of Ceruloplasmin expression	104	51	2.8×10^{-92}
3' -UTR-mediated translational regulation	104	51	2.8×10^{-92}
Neuronal System	272	84	8.4×10^{-92}
SRP-dependent cotranslational protein targeting to membrane	105	51	9.5×10^{-92}
Eukaryotic Translation Initiation	112	52	2.0×10^{-90}
Cap-dependent Translation Initiation	112	52	2.0×10^{-90}


Gene set over-representation analysis (hypergeometric test) for Reactome pathways in SLIPT partners for *CDH1*

4.4.2 Synthetic Lethal Expression Profiles

The expression profiles of candidate synthetic lethal partners detected by SLIPT and mtSLIPT in stomach cancer were plotted against clinical characteristics as described in section for breast cancer data in Section 4.1.2 (shown in Figures 4.12 and G.1 respectively). As expected the majority of *CDH1* mutant samples had low expression of *CDH1* and were the diffuse type of stomach cancer.

The SLIPT partners of *CDH1* exhibited similar clustering in stomach cancer to breast cancer, replicating the diverse roles of elevated partner genes in different clinical samples. Specifically (in Figure 4.12), the diffuse type stomach cancers had higher expression of the candidate synthetic lethal partners (where *CDH1* has a role as a driver mutation), despite an unbiased clustering. This is consistent with compensating expression of synthetic lethal partners under loss of *CDH1*, as suggested by Lu *et al.* (2015). The pathway composition of gene clusters for stomach cancer (shown in Table F.2) was also highly concordant with breast cancer findings (shown in Table 4.3). These included replicated of translation (Cluster 1), immune functions (Cluster 2), G α s signalling (Cluster 3), and further support for the roles of GPCRs and the extracellular matrix (Cluster 4) in the synthetic lethal partners and functions of *CDH1*, replicated across stomach and breast cancers. Clusters 1 and 4, which had particularly high expression of SLIPT candidate partner genes in the diffuse subtype, also had the most significant over-representation of pathways.

There was less variation between the expression profiles of mtSLIPT partners of *CDH1* in stomach cancer, although clusters were still detectable (as shown in Figure G.1). While the genes and pathways detected was less significant (due to lower sample size), the composition of clusters was further indicative for the roles of extracellular matrix (including elastic fibres), immune functions, and the cell signalling.



4.4.3 Comparison to Primary Screen

The number of genes detected by both SLIPT in TCGA stomach cancer data and siRNA in breast cell lines (shown in Figure F.1) was also not a significant overlap (as observed for breast cancer in Figure 4.2). This was particularly the case of mtSLIPT against *CDH1* mutation in stomach cancer which detected very few genes (as shown in Figure G.2) due to low sample size and mutation frequency.

This smaller overlap can also be attributed to the tissue-specific differences between the stomach cancers and the breast cells used for the experimental model (Chen *et al.*, 2014). Nevertheless, many genes were detected across SLIPT in stomach cancers and the experimental screen (Telford *et al.*, 2015) and the pathways detected were consistent with prior observations in breast cancer. Despite differences in the specific genes detected, the functions of *CDH1* were conserved across epithelial cancers in different tissues and synthetic lethal inhibition of interacting pathways may be effective against molecular targets such as *CDH1* inactivation across tissue types.

However, the pathway composition of SLIPT-specific genes and those replicated with the siRNA primary screen (Telford *et al.*, 2015) were highly concordant between the pathways identified by SLIPT in TCGA stomach cancer (shown in Table F.3) and pathways previously identified in TCGA breast cancer (shown in Table 4.4). In both cases, translation and immune pathways were highly over-represented in SLIPT-specific genes, which we would not expect to be detected by siRNA screening in cell lines, as discussed in Section 4.2.1.4. In addition, the extracellular matrix was supported by in stomach cancer. While the pathways identified by specifically by SLIPT in stomach cancer or siRNA screening were similar to those observed for breast cancer (in Table 4.4), the pathways over-represented in the intersection for stomach cancer SLIPT candidates and the siRNA primary screen (Telford *et al.*, 2015) also had a clear over-representation of signalling pathways, although they differed from those observed in breast cancer SLIPT candidates. GPCR signalling was supported in genes detected in both TCGA stomach cancer and screening, including *Gαq*, *Gαs*, serotonin receptors, and class A signalling (shown in more detail in Table F.5). In addition MAPK and NOTCH signalling pathways were detected. These replicate the findings in breast cancer and show consistent detection of signalling pathways in stomach cancer despite less genes being detected by SLIPT and patient samples differing from the tissue in which the experiments were conducted.

Similarly, the SLIPT-specific gene candidates against *CDH1* mutation (shown in Table G.4) replicated pathways observed in breast cancer (shown in Table D.4), despite

a lower number of genes detected. In particular, the extracellular matrix and elastic fibres were over-represented. While the number of genes overlapping with the siRNA was too low to be amenable to pathway analysis, there is further indication that members of these genes replicated across mutation SLIPT analyses include cell-membrane, elastic fibre, and GPCR signalling genes.

4.4.3.1 Resampling Analysis

Similarly, resampling for SLIPT specific candidates (shown in Tables F.4 and G.5) replicated many of the most highly over-represented pathways in stomach cancer. These include translational, immune, GPCR signalling, and elastic fibres, consistent with previous analyses in breast cancer (shown in Tables 4.5 and D.5).

While fewer pathways were supported by resampling for the intersection of SLIPT and experimental screen (Telford *et al.*, 2015) candidate partners in stomach cancer than breast cancer, many of those detected (shown in Table F.5) replicate those detected in breast cancer (shown in Tables 4.6 and D.6). The pathways detected by both permutation and over-representation were more likely to be replicated across stomach and breast cancer than those detected by over-representation alone, supporting the use of this procedure to detect synthetic lethal pathways applicable across cancer types. The include *Gαs* signalling and elastic fibre formation as discussed for breast cancer (in Section 4.2.1.4.1)

While many pathways were detected by resampling for mtSLIPT against *CDH1* mutation in stomach cancer (shown in Table G.6), there were not enough genes detected by both mtSLIPT and the siRNA primary screen to determine over-represented pathways. Therefore this may be due to small numbers of genes which does not constitute support for pathway composition. However, this under-powered analysis does not preclude the replicated synthetic lethal pathways detected across SLIPT expression analyses in TCGA breast and stomach cancer data with an accompanying siRNA primary screen (Telford *et al.*, 2015). Rather this further supports the use of SLIPT to test against low expression of query genes as measure of gene inactivation to avoid this issue, despite mutation (which often produces similar results) being more indicative of complete gene inactivation.

4.4.4 Metagene Analysis

Metagene analysis (as conducted in Section 4.3.4) was also performed for TCGA stomach cancer expression data, using Reactome pathways. These results (as shown in Table F.6) provided further support for signalling and extracellular processes as synthetic

lethal pathways across stomach and breast cancer. Namely, cell-cell communication, VEGF signalling, and various GPCR pathways were detected.

Signalling and immune pathways were also supported by mtSLIPT analysis of meta-gene pathway expression against *CDH1* mutation, as shown in Table G.7. Although these results were generally less statistically significant than expression analyses. Signalling pathways detected as synthetic lethal metagenes include prostacyclin, SCF-KIT, ERK, MAPK, NGF, VEGF, and PI3K/AKT. The innate immune response, the inflammasome, and integrin signaling were also implicated to be synthetic lethal with *CDH1 mutations*. Cell surface interactions, cholesterol biosynthesis, and platelet homeostasis also support the role of extracellular processes in proliferation of *CDH1* deficient cancers and interactions of *CDH1* with the extracellular environment that was not tested in the cell line experimental screen.

4.5 Global Synthetic Lethality

Global levels of synthetic lethality were analysed to address concerns raised by the high numbers of synthetic lethal candidates for *CDH1*. The SLIPT procedure (as described in Section 3.1) was performed with each possible query gene from the TCGA breast cancer RNA-Seq dataset. Due to the computational demands of this procedure, it was performed on the New Zealand eScience Infrastructure Intel Pan supercomputer (as described in Section 2.5.3).

The observed number of SLIPT appears to be typical for most genes in the TCGA breast RNA-Seq dataset as shown in Figure 4.13. This figure was actually lower than the majority (95%) of genes tested, although *CDH1* was ranked higher for a similar in SLIPT analysis of TCGA stomach cancer data, shown in Figure H.1. The differences in sample size make these analyses difficult to compare but (in either case), the number of partners detected for *CDH1* is not unexpected, even when adjust for multiple comparisons across candidate partners.

The number of detected candidates reported here is higher than in Figures 4.2 and F.1 because these excluded genes not tested by the siRNA primary screen (Telford *et al.*, 2015) for comparison with it. For an statistically rigorous measure of global synthetic lethality, multiple comparison procedures would need to be performed for all pairs of genes tested. However, only partner genes for each query SLIPT analysis were performed for the purposes of comparing the number of partners predicted with those observed for *CDH1* throughout this thesis.




Figure 4.13: **Synthetic lethal partners across query genes.** Global synthetic lethal pairs were examined across the genome in TCGA breast expression data by applying SLIPT across query genes. The high number of predicted partners for *CDH1* was typical for a human gene and lower than many other genes.

4.5.1 Hub Genes

The genes with the most synthetic lethal interactions by this SLIPT analysis are the “hub” genes of a synthetic lethal network. These genes with the highest number of candidate partners detected by SLIPT in TCGA breast cancer expression data are summarised in Table 4.9. These include several genes involved in cellular signalling such as *TGFBR2*, *PDGFRA*, *FAM126A*, *KCTD12*, *MAML2*, and *CAV1*. Gene regulation including chromatin, DNA, and RNA bindings genes were also observed as hub genes such as *CELF2*, *PLAGL1*, *TSHZ2*, *FOXO1*, and *SVEP1*. Genes involved in the cellular membrane such as *ANXA1* and *FAM171A1* were also observed in addition to genes specifically implicated in cell adhesion and tight junctions such as *TNS1*, *BOC*, *AMOTL1*, *FAT4*, and *EPB41L2*.

Table 4.9: Query synthetic lethal genes with the most SLIPT partners

Gene	Direction	raw p-value	p-value (FDR)	SLIPT raw p-value	SLIPT (FDR)
<i>TGFBR2</i>	8134	17982	17973	8007	8006
<i>A2M</i>	8571	17605	17583	8345	8339
<i>TNS1</i>	8019	17949	17934	7874	7873
<i>PROS1</i>	8539	17668	17642	8317	8310
<i>ANXA1</i>	9085	17330	17302	8689	8682
<i>CELF2</i>	8665	17406	17368	8370	8355
<i>BOC</i>	8694	17371	17348	8384	8381
<i>PLAGL1</i>	8792	17361	17327	8448	8436
<i>PDGFRA</i>	8296	17650	17621	8095	8087
<i>FAM171A1</i>	8874	17560	17533	8567	8562
<i>FAM126A</i>	8510	17383	17356	8184	8178
<i>TSHZ2</i>	7942	17983	17976	7787	7786
<i>KCTD12</i>	8366	17651	17621	8115	8108
<i>MAML2</i>	8336	17537	17503	8069	8061
<i>FOXO1</i>	8027	17753	17737	7840	7836
<i>AMOTL1</i>	8425	17388	17347	8147	8139
<i>FAT4</i>	8111	17750	17732	7925	7919
<i>CAV1</i>	8645	17491	17464	8342	8331
<i>SVEP1</i>	7945	17859	17842	7791	7784
<i>EPB41L2</i>	8415	17327	17296	8097	8092

Genes with the most candidate SL partners SLIPT in TCGA breast expression data with the number of partner genes predicted by direction criteria and χ^2 testing separately and combined as a SLIPT analysis. Where specified, the p-values for the χ^2 test were adjusted for multiple tests (FDR).

Genes involved in adhesion and tight junctions were also hub genes in stomach cancer (shown in Table H.1) such as *HEG1*, *FAT4*, *NFASC*, *LAMA4*, *LAMC1*, *TNS1*, and *AMOTL1*. These also included cytoskeletal genes such as *ANK2*, *TTC28*, and *MACF1*. Cancer genes were also among hub genes across breast and stomach cancer such as *BOC*, *FAT4*, and *MRVI1*.

It is therefore unsurprising that signalling and regulatory genes have been detected throughout this thesis. Not only are they suitable targets for anti-cancer therapy, they are also highly interacting genes themselves and so it is plausible that their interactions would be detectable by SLIPT. This is consistent with the established role of aberrant signalling and gene regulation in proliferation and survival of tumours and the importance of these pathways in development with highly redundant functions across many genes under complex regulation. These are also highly amenable to detection by SLIPT analysis of expression data since their functions are dynamically regulated with corresponding changes in expression.

Cytoskeletal, membrane bound, and extracellular matrix genes are also among highly interacting synthetic lethal hubs, including focal adhesion, tight junctions, microtubules, and fibronectin. These support the use of synthetic lethal interactions to

target *CDH1*, as a tumour suppressor gene involved in these functions. Cellular structure and cell-cell interactions are thus important functions with highly redundant genes for which there are many feasible synthetic lethal interactions by which to understand regulation of cellular functions. These functions may also be exploited as vulnerabilities in cancer as they are frequently disrupted in cancers, including HDGC where loss of *CDH1* is a driver of cancer proliferation and malignancy.

4.5.2 Hub Pathways

Pathways over-represented among TCGA breast cancer hub genes (as shown in Table 4.10) particularly support the importance of signalling pathways, such as the PI3K/AKT pathway, as synthetic lethal hubs. The highly redundant natures of cell-cell interaction and the extracellular matrix functions was also further supported.

Table 4.10: Pathways for genes with the most SLIPT partners

Pathways Over-represented	Pathway Size	SL Genes	p-value	p-value (FDR)
Constitutive Signaling by Aberrant PI3K in Cancer	56	10	8.4×10^{-16}	8.7×10^{-13}
PI3K/AKT Signaling in Cancer	78	11	2.1×10^{-14}	1.1×10^{-11}
Role of LAT2/NTAL/LAB on calcium mobilization	96	12	7.7×10^{-14}	2.2×10^{-11}
Complement cascade	33	7	1.2×10^{-13}	2.2×10^{-11}
Cell surface interactions at the vascular wall	99	12	1.6×10^{-13}	2.2×10^{-11}
PI3K events in ERBB4 signaling	87	11	2.6×10^{-13}	2.2×10^{-11}
PIP3 activates AKT signaling	87	11	2.6×10^{-13}	2.2×10^{-11}
PI3K events in ERBB2 signaling	87	11	2.6×10^{-13}	2.2×10^{-11}
PI-3K cascade:FGFR1	87	11	2.6×10^{-13}	2.2×10^{-11}
PI-3K cascade:FGFR2	87	11	2.6×10^{-13}	2.2×10^{-11}
PI-3K cascade:FGFR3	87	11	2.6×10^{-13}	2.2×10^{-11}
PI-3K cascade:FGFR4	87	11	2.6×10^{-13}	2.2×10^{-11}
Extracellular matrix organization	238	22	4.7×10^{-13}	3.6×10^{-11}
Muscle contraction	62	9	4.9×10^{-13}	3.6×10^{-11}
PI3K/AKT activation	90	11	5.5×10^{-13}	3.8×10^{-11}
GAB1 signalosome	91	11	7.1×10^{-13}	4.6×10^{-11}
Smooth Muscle Contraction	28	6	2.4×10^{-12}	1.5×10^{-10}
Response to elevated platelet cytosolic Ca^{2+}	82	10	2.6×10^{-12}	1.5×10^{-10}
Signaling by SCF-KIT	126	13	3.0×10^{-12}	1.6×10^{-10}
Signaling by FGFR	143	14	5.0×10^{-12}	2.2×10^{-10}

Gene set over-representation analysis (hypergeometric test) for Reactome pathways in the top 500 “hub” genes with the most candidate synthetic lethal partners by SLIPT analysis of TCGA breast expression data

Pathway over-representation for synthetic lethal hub genes was replicated in TCGA stomach cancer expression data. However, these pathways differ considerably from breast cancer, as shown in Table H.2. Cell-cell interactions and extracellular matrix pathways, including elastic fibres, were also among the hub genes for stomach cancer.

The signalling pathways differ as expected in a different tissue type, although BMP and PAK signalling were detected as hub gene functions.

4.6 Replication in cell line encyclopaedia

As breast cancer cell lines are the experimental system in which many cancer genetics and drug targets are investigated, these were analysed in addition to patient samples from TCGA. The cancer cell line encyclopaedia (CCLE) is a resource for genomics profiles across a range of cell lines. These have also been used to generate synthetic lethal candidates for comparison to those in experimental screen and predictions from TCGA expression data.

Table 4.11: Pathways for *CDH1* partners from SLIPT in CCLE

Pathways Over-represented	Pathway Size	SL Genes	p-value (FDR)
Cell Cycle	442	207	1.2×10^{-215}
Cell Cycle, Mitotic	365	180	2.9×10^{-209}
Signaling by Rho GTPases	311	136	9.4×10^{-156}
M Phase	212	104	8.8×10^{-145}
Infectious disease	289	123	1.3×10^{-142}
RHO GTPase Effectors	207	98	5.3×10^{-135}
HIV Infection	200	94	2×10^{-130}
Separation of Sister Chromatids	140	77	5.6×10^{-128}
Organelle biogenesis and maintenance	258	107	1.4×10^{-127}
Chromatin modifying enzymes	181	87	4.7×10^{-126}
Chromatin organization	181	87	4.7×10^{-126}
Mitotic Metaphase and Anaphase	149	78	1.2×10^{-124}
Mitotic Anaphase	148	77	6.3×10^{-123}
Developmental Biology	421	142	1.6×10^{-121}
RHO GTPases Activate Formins	94	60	5.3×10^{-118}
Mitotic Prometaphase	93	59	5.4×10^{-116}
Hemostasis	421	138	7.2×10^{-116}
Adaptive Immune System	397	132	3.2×10^{-115}
Assembly of the primary cilium	143	72	2.4×10^{-114}
Transcription	133	68	6.2×10^{-111}

Gene set over-representation analysis (hypergeometric test) for Reactome pathways in SLIPT partners for *CDH1*

The cancer cell line encyclopaedia provides further support for synthetic lethal genes and pathways that may be applicable across cell types and reproducible in experimental systems. In contrast to the homogeneous pooled cell samples of patients, the cell lines provide a genetically homogeneous cell population in which to examine molecular functions and as a preclinical model of cancerous disease. The complete set of 1037 cell lines was tested for synthetic lethality across tissues, in addition to the 59 breast cell lines and 38 stomach cell lines being tested separately for partners of *CDH1*. Synthetic lethal genes were detected by SLIPT (as described in Section 3.1) and over-represented synthetic lethal Reactome pathways (as described in Section 2.3.2).

Synthetic lethal gene candidates were detectable by SLIPT across each of these sample sets of cells lines (as shown in Tables I.1–I.3. Although these were most highly significant across the samples in the CCLE expression dataset (as shown in Table I.1) and included genes detected in prior analyses such as *VIM*, *ZEB2*, *EMP3*. Pathways were also highly over-represented among synthetic lethal candidates for the full CCLE dataset (as shown in Table 4.11) including Rho GTPase (GPCRs), immune, and gene regulation (chromatin and transcription). This is unexpected since immune pathways would not be expected to be detectable in isolated cell lines, although this could be attributed to cytokine and integrin signalling occurring the cancer cells in addition to interactions with immune cells in the tumour microenvironment (which could not be distinguished in patient samples). Cell cycle and mitosis were among the highest synthetic lethal pathways across cell lines supporting *CDH1* deficient cells having aberrant cell signalling and consequences for proliferation such as cancer cells. However, cell cycle genes were not as strongly supported in TCGA patient samples or the siRNA screen (Telford *et al.*, 2015) and they may not be applicable to epithelial tissues such as breast or stomach cancer or amenable to selective inhibition in experimental models.

Synthetic lethal pathways specific to SLIPT candidates from breast cell lines (as shown in Table 4.12) were more consistent with previous observations, particularly the established role of E-cadherin in cell junctions and the Adherens complex. Although the number of SLIPT candidate genes detected in stomach cell lines was insufficient to replicate the findings in breast cell lines to TCGA patient samples. However, SLIPT candidates across breast and stomach CCLE cell lines were over-represented (as shown in Table I.5) for similar pathways to breast cell lines with additional support for extracellular matrix pathways including elastic fibres which were replicated with resampling across breast and stomach TCGA analyses and the primary siRNA screen Telford *et al.* (2015).

Table 4.12: Pathways for *CDH1* partners from SLIPT in breast CCLE

Pathways Over-represented	Pathway Size	SL Genes	p-value (FDR)
Cell junction organization	71	5	0.006
Adherens junctions interactions	29	3	0.006
Dermatan sulfate biosynthesis	11	2	0.006
Non-integrin membrane-ECM interactions	52	4	0.006
Regulation of pyruvate dehydrogenase (PDH) complex	12	2	0.0069
Cell-extracellular matrix interactions	17	2	0.021
Pyruvate metabolism	17	2	0.021
Cell-cell junction organization	46	3	0.039
Synthesis of substrates in N-glycan biosynthesis	50	3	0.057
Detoxification of Reactive Oxygen Species	26	2	0.082
Keratan sulfate biosynthesis	28	2	0.092
Laminin interactions	28	2	0.092
Cell-Cell communication	118	5	0.12
Keratan sulfate/keratin metabolism	32	2	0.12
Opioid Signalling	63	3	0.12
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide) and transfer to a nascent protein	63	3	0.12
Intraflagellar transport	34	2	0.14
Signaling by Retinoic Acid	36	2	0.16
Pyruvate metabolism and Citric Acid (TCA) cycle	36	2	0.16
Nef mediated downregulation of MHC class I complex cell surface expression	10	1	0.22

Gene set over-representation analysis (hypergeometric test) for Reactome pathways in SLIPT partners for *CDH1*

4.7 Discussion

4.7.1 Strengths of the SLIPT Methodology

Synthetic lethal discovery with SLIPT used established statistical procedures identify putative partner genes from gene expression data. Such use of the χ^2 -value is amenable to pathway or permutation analyses and could feasibly be applied to other disease gene or pair-wise across the genome. Although genome-wide approaches were unable to find informative candidate genes for E-cadherin Lu *et al.* (2015). Synthetic lethal discovery in cancer has focused on genes with severe cellular mutant phenotypes, such as essential genes or the oncogenes *TP53* and *AKT* Lu *et al.* (2015); Tiong *et al.* (2014); Wang and Simon (2013), with other cancer genes, such as *CDH1*, requiring more focused investigations. Prior computational approaches for synthetic lethal discovery, in cancer, vary widely (Jerby-Arnon *et al.*, 2014; Lu *et al.*, 2015; Tiong *et al.*, 2014; Wappett *et al.*, 2016). There is no consensus for which for the approach is more appropriate and they are difficult to compare as they either do not have a released code implementation or do not make predictions solely from normalised expression data.

However, the query-based approach demonstrated by SLIPT analysis is suitable for wider application on expression data and augmenting experimental studies such as high-throughput screens. This approach has identified biologically plausible synthetic lethal pathways for *CDH1*, triaged candidates from experimental screening (Telford *et al.*, 2015), and replicates genes and pathways across breast and stomach cancers datasets. In addition, SLIPT avoids critical assumptions underlying the design of some prior approaches such as coexpression of synthetic candidates or that they will have known (annotated) similarities in function.

The DAISY methodology Jerby-Arnon *et al.* (2014), which took a similar query-based approach with the tumour suppressor *VHL*, has been critiqued for being too stringent Lu *et al.* (2015) which impedes pathway analysis. Since functional redundancy does not require genes to be expressed at the same time, the SLIPT approach does not assume co-expression of synthetic lethal genes which may enrich for synthetic lethal genes in established coregulated pathways. Rather, the interpretation of synthetic lethality for SLIPT was similar to other computational methods based on ‘co-loss under-representation’, ‘compensation’, or ‘simultaneous differential expression’ Lu *et al.* (2015); Tiong *et al.* (2014); Wang and Simon (2013).

Genomics analyses are prone to false-positives and require statistical caution, particularly where working with gene-pairs scale up the number of multiple tests drastically, at the expense of statistical power. Experimental screens for synthetic lethality are also error-prone, especially with false-positives, raising the need for understanding the expected behaviour and number of functional relationships and genetic interactions in the genome, or in discovery of synthetic lethal partners of a particular query gene. Thus analyses throughout this thesis have focused on querying for partners of a particular gene of interest. Statistical modelling and simulations (in Section 3.3 and Chapter 6) will further support the design decisions underlying SLIPT analysis and its strengths over other approaches.

4.7.2 Synthetic Lethal Pathways for E-cadherin

As specific genes were difficult to replicate across experiments, gene expression profiles for synthetic lethal partners must be more complex than originally expected to directly compensate for loss of query gene or completely lack (or clearly under-representation) mutual loss (Jerby-Arnon *et al.*, 2014; Kelly, 2013; Lu *et al.*, 2015). The predicted synthetic lethal partners of *CDH1* (with FDR correction) were investigated with gene expression profiles and clinical variables to find relationships in gene expression, gene

function, and clinical characteristics. The large number of hits indicate that synthetic lethal detection is error-prone and identifying genes relevant for clinical application will be difficult without a supporting biological pathway rationale. As such, investigations into the genes identified by SLIPT, correlation structure between them, and those which were validated by experimental screening (Telford *et al.*, 2015) focused on the pathway level throughout this Chapter. Similarly, comparisons across analyses were largely made at the pathway level, including comparisons between expression and mutation, breast and stomach TCGA datasets, and patient sample data with cell line expression profiles.

Potential synthetic lethal partners of *CDH1* identified by SLIPT had many distinct functions, with each gene cluster highly expressed in different patient subgroups (Figure 4.1). The expression profiles of the SL partners of *CDH1* predicted from the TCGA breast cancer RNA-Seq data (expected to have compensating high or stable expression) and their corresponding functional enrichment found subgroups of genes with functional organisation particularly among *CDH1* low breast tumours. Ductal breast cancers show higher expression of synthetic lethal partners suggesting treatment would be more effective in this tumour subtype. However, there is consistently low expression of SL partners in estrogen receptor negative tumours, although this is independent of tumour stage and consistent with poor prognosis in these patients and could inform other treatment strategies or prevent ineffective treatment further impacting quality of life in these patients. These results suggest that synthetic lethal partner expression varies between patients; that these different tumour classes would react differently to the same treatment; that treatment of different pathways and combinations in different patients is the most effective approach to target genes compensating for *CDH1* gene loss; and the expression of synthetic partners could be a clinically important biomarker.

The pathways that synthetic lethal partners of *CDH1* identified by SLIPT were involved in a diverse range of biological functions and differed to those detected experimentally. This discrepancy may be accounted for by gene expression analyses detecting both synthetic lethal partners (as screened for experimentally Telford *et al.* (2015)) and their downstream targets (not detected by siRNA), capturing the wider pathways and mechanisms involved in synthetic lethality with *CDH1* inactivation. In particular, GPCR phosphorylation cascades (which regulates gene expression and translation in cancers Gao and Roux (2015)) were predicted to be synthetic lethal with *CDH1*. The predicted synthetic lethal partners occurred across functionally distinct pathways, including characterised functions of *CDH1*. The most consistently supported pathways

include elastic fibres in the extracellular matrix, GPCR signalling, and translation presenting vulnerabilities for *CDH1* deficient cancer cells from extracellular stimuli to the core growth mechanisms of a cell.

This diversity in synthetic lethal functions is consistent with the wide ranging role of *CDH1* in cell-cell adhesion, cell signalling, and the cytoskeletal structure of epithelial tissues. Pathway structure may be relevant to identifying potential drug targets from gene expression signatures, indicating downstream effector genes and mechanisms leading to cell inviability. Identification of distinct synthetic lethal gene clusters may further lead to the elucidation of drug resistance mechanisms. While these pathways are indicative of the main functions of E-cadherin and synthetic lethal partners, it remains to identify the genes within these pathways that are the most actionable or supported across SLIPT analysis in patient samples and detected by experiments in preclinical models (Chen *et al.*, 2014; Telford *et al.*, 2015). The specific genes within key pathways will be discussed in Chapter 5, along with further investigations into their relation to pathway structure. While these are important clinical implications, the synthetic lethal predictions lack enough confidence for direct translation into pre-clinical models or clinical applications leading to a need for statistical modelling and simulation of synthetic lethality in genomics expression data.

These synthetic lethal pathways have potential clinical implications, particularly those supported in pre-clinical models and in patient expression data. However, further validation of gene candidates will be necessary to ensure that these are able to be reproduced in further pre-clinical studies, they are applicable to tumours *in vivo*, and that effective inhibitory agents can be repurposed or designed against them.

4.7.3 Replication and Validation

4.7.3.1 Integration with siRNA Screening

The pathway composition across computational and experimental synthetic lethal candidates was informative with over-representation (Table 4.4) and supported by resampling analysis (Table 4.6), despite a modest intersection of genes between them (Figure 4.2). Either approach may be significant for a pathway in this intersection without being supported by the other: resampling analysis may support pathways that were not over-represented due to small effect sizes, thus both tests are required for a candidate pathway.

The pathways detected by both over-representation and resampling are the strongest candidates for further investigation and the pathway structure analyses in Chapter 5

will focus on these pathways detected by both over-representation and resampling. Particularly, those replicated across datasets or with pathway metagenes. In addition to GPCR pathways detected across these analyses, the PI3K cascade will also be investigated in Chapter 5, this signalling pathway is a well characterised mediator between GPCR receptors and regulation of translation (Gao and Roux, 2015) (both detected throughout this Chapter) and exhibited unexpected behaviour with pathway the metagenes (in Section 4.3). This pathway is activated by protein Phosphorylation states and thus inactivatino may not be detectable with expression.

However, the SLIPT approach was shown to be predictive of which siRNA primary screen candidate partners of *CDH1* were validated in a secondary screen (as shown in Appendix C). These results further support SLIPT for identifying robust synthetic lethal candidates which can be validated and as a triage approach for interpreting screening experiments.

4.7.3.2 Replication across Tissues and Cell lines

Furthermore, synthetic lethal partners identified by SLIPT were replicated across breast and stomach cancer. These were particularly concordant at the pathway level, as expected between tissues since synthetic lethal pathways have higher conservation between species (Dixon *et al.*, 2008). These findings support gene functions conserved across *CDH1* deficient cancers in breast and stomach tissues, presenting vulnerabilities that could be applied against molecular targets in both cancers. In addition, these analyses serve as a replication across independent patient cohorts from breast and stomach cancers, decreasing the likelihood of the synthetic lethal pathways detected being false positives or artifacts of either dataset.

Synthetic lethal pathways were also replicated across expression analyses of TCGA patient samples in heterogeneous tumours and homogeneous cell line isolates. This further supports that the subset of synthetic lethal functions detectable in experimental models (Chen *et al.*, 2014; Telford *et al.*, 2015) would be applicable tumours of patients with *CDH1* deficient cancers.

There are many gene functions replicated across breast cancer gene expression analyses. Many of these were also replicated with mutation analysis and with stomach cancer or cell line expression data. These pathways were more consistent across replication analyses than previous investigations with TCGA microarray data Kelly (2013).

4.8 Summary

We have developed a simple, interpretable, computational approach to predict synthetic lethal partners from genomics data. The analyses focus on gene expression data as it is widely available for applications in other cancers and other disease genes, particularly those with malignant loss of function.

This approach has been applied to robustly detect synthetic lethal pathways for the E-cadherin (*CDH1*) in TCGA breast cancer molecular profiles with comparisons to experimental screening (Telford *et al.*, 2015) in cell lines, and replication in TCGA stomach cancer molecular profiles and across cell types in the cancer cell line encyclopaedia. The pathway replicated across several analyses included extracellular matrix pathways (such as elastic fibres formation), cell signalling (including GPCRs), and core gene regulation and translation processes crucial for the growth and proliferation of cancer cells. These pathways show evidence of non-oncogene addiction for *CDH1* deficient cells and present vulnerabilities which may be exploited for specific treatment against *CDH1* mutations in HCGC and sporadic cancers. There was also support for synthetic lethal pathways with *CDH1* in cell adhesion and cytoskeletal processes to which *CDH1* belongs, supporting the finding that synthetic lethality occurs within biological pathways (Boone *et al.*, 2007; Kelley and Ideker, 2005).

While translational and immune pathways detected by SLIPT were not supported by primary siRNA screening (Telford *et al.*, 2015), these were replicated across various analyses. Due to the differences between an experimental cell line model (Barretina *et al.*, 2012; Chen *et al.*, 2014; Fece de la Cruz *et al.*, 2015) and patient molecular profiles (Bass *et al.*, 2014; TCGA, 2012), these would not be expected to be completely concordant. Furthermore, many pathways are difficult to test in an isolated experimental system. Nevertheless, many of the genes and pathways detected by SLIPT are suitable to inform further investigations and triage of therapeutic targets against *CDH1* deficient tumours in combination with experimental screening.

A characteristic of gene interaction networks is a scale-free topology leading to highly interacting hub genes, these represent important genes in a functional network. Cell surface interactions, the extracellular matrix, and cell signalling (particularly PI3K/AKT signalling) were also found to be synthetic lethal hubs with more interactions detected than other genes. This indicates that these pathways are functionally important to survival of cancer cells since they are subject to high functional redundancy, despite frequent disruptions in cancer. These pathways being involved in

a disproportionate number of synthetic lethal interactions is also consistent with their detection for *CDH1*.

Thus synthetic lethal pathways have been identified using TCGA patient molecular profiles, CCLE cancer cell line expression data, and experimental screening results. Some of these were robustly replicated across these datasets and against *CDH1* mutation or expression analysis. However, there remains the need to identify actionable genes within these pathways, relationships with experimental candidates, and how these pathways may affect viability when lost. While the genes identified between these analyses were less concordant the results of the TCGA breast cancer analysis will be used to test pathway structure relationships and further examine the synthetic lethal genes detected in the following Chapter.

Aims

- Pathway Structure of Candidate Synthetic Lethal Genes for *CDH1* from TCGA breast data
- Comparisons to Experimental siRNA Screen Candidates
- Replication of Pathways across in TCGA Stomach data

Summary

- We have developed a Synthetic Lethal detection method that generates a high number of synthetic lethal candidates
- Pathways in cell signalling, extracellular matrix, and cytoskeletal functions were supported with experimental candidates and the known functions of E-cadherin
- Several candidate pathways were supported by mutation analysis and replicated across breast and stomach cancer
- Translation and immune functions were uniquely detected by the computational approach which may be explained by differences between patient samples and cell line models
- There remains the need to identify actionable genes within these pathways, relationships with experimental candidates, and how these pathways may affect viability when lost

References

- Aarts, M., Bajrami, I., Herrera-Abreu, M.T., Elliott, R., Brough, R., Ashworth, A., Lord, C.J., and Turner, N.C. (2015) Functional genetic screen identifies increased sensitivity to weel inhibition in cells with defects in fanconi anemia and hr pathways. *Mol Cancer Ther*, **14**(4): 865–76.
- Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C.D., Annala, M., Aprikian, A., Armenia, J., Arora, A., *et al.* (2015) The Molecular Taxonomy of Primary Prostate Cancer. *Cell*, **163**(4): 1011–1025.
- Adamski, M.G., Gumann, P., and Baird, A.E. (2014) A method for quantitative analysis of standard and high-throughput qPCR expression data based on input sample quantity. *PLoS ONE*, **9**(8): e103917.
- Adler, D. (2005) *vioplot: Violin plot*. R package version 0.2.
- Agarwal, S., Deane, C.M., Porter, M.A., and Jones, N.S. (2010) Revisiting date and party hubs: Novel approaches to role assignment in protein interaction networks. *PLoS Comput Biol*, **6**(6): e1000817.
- Agrawal, N., Akbani, R., Aksoy, B.A., Ally, A., Arachchi, H., Asa, S.L., Auman, J.T., Balasundaram, M., Balu, S., Baylin, S.B., *et al.* (2014) Integrated genomic characterization of papillary thyroid carcinoma. *Cell*, **159**(3): 676–690.
- Akbani, R., Akdemir, K.C., Aksoy, B.A., Albert, M., Ally, A., Amin, S.B., Arachchi, H., Arora, A., Auman, J.T., Ayala, B., *et al.* (2015) Genomic Classification of Cutaneous Melanoma. *Cell*, **161**(7): 1681–1696.
- Akobeng, A.K. (2007) Understanding diagnostic tests 3: receiver operating characteristic curves. *Acta Paediatrica*, **96**(5): 644–647.
- American Cancer Society (2017) Genetics and cancer. <https://www.cancer.org/cancer/cancer-causes/genetics.html>. Accessed: 22/03/2017.

- American Society for Clinical Oncology (ASCO) (2017) The genetics of cancer. <http://www.cancer.net/navigating-cancer-care/cancer-basics/genetics/genetics-cancer>. Accessed: 22/03/2017.
- Anjomshoaa, A., Lin, Y.H., Black, M.A., McCall, J.L., Humar, B., Song, S., Fukuzawa, R., Yoon, H.S., Holzmann, B., Friederichs, J., *et al.* (2008) Reduced expression of a gene proliferation signature is associated with enhanced malignancy in colon cancer. *Br J Cancer*, **99**(6): 966–973.
- Araki, H., Knapp, C., Tsai, P., and Print, C. (2012) GeneSetDB: A comprehensive meta-database, statistical and visualisation framework for gene set analysis. *FEBS Open Bio*, **2**: 76–82.
- Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M., Davis, A.P., Dolinski, K., Dwight, S.S., Eppig, J.T., *et al.* (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat Genet*, **25**(1): 25–29.
- Ashworth, A. (2008) A synthetic lethal therapeutic approach: poly(adp) ribose polymerase inhibitors for the treatment of cancers deficient in dna double-strand break repair. *J Clin Oncol*, **26**(22): 3785–90.
- Audeh, M.W., Carmichael, J., Penson, R.T., Friedlander, M., Powell, B., Bell-McGuinn, K.M., Scott, C., Weitzel, J.N., Oaknin, A., Loman, N., *et al.* (2010) Oral poly(adp-ribose) polymerase inhibitor olaparib in patients with *BRCA1* or *BRCA2* mutations and recurrent ovarian cancer: a proof-of-concept trial. *Lancet*, **376**(9737): 245–51.
- Babyak, M.A. (2004) What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. *Psychosom Med*, **66**(3): 411–21.
- Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., Flanagan, A., Teague, J., Futreal, P.A., Stratton, M.R., *et al.* (2004) The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. *Br J Cancer*, **91**(2): 355–358.
- Barabási, A.L. and Albert, R. (1999) Emergence of scaling in random networks. *Science*, **286**(5439): 509–12.

- Barabási, A.L. and Oltvai, Z.N. (2004) Network biology: understanding the cell’s functional organization. *Nat Rev Genet*, **5**(2): 101–13.
- Barrat, A. and Weigt, M. (2000) On the properties of small-world network models. *The European Physical Journal B - Condensed Matter and Complex Systems*, **13**(3): 547–560.
- Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J., Lehar, J., Kryukov, G.V., Sonkin, D., *et al.* (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature*, **483**(7391): 603–607.
- Barry, W.T. (2016) *safe: Significance Analysis of Function and Expression*. R package version 3.14.0.
- Baryshnikova, A., Costanzo, M., Dixon, S., Vizeacoumar, F.J., Myers, C.L., Andrews, B., and Boone, C. (2010a) Synthetic genetic array (sga) analysis in *saccharomyces cerevisiae* and *schizosaccharomyces pombe*. *Methods Enzymol*, **470**: 145–79.
- Baryshnikova, A., Costanzo, M., Kim, Y., Ding, H., Koh, J., Toufighi, K., Youn, J.Y., Ou, J., San Luis, B.J., Bandyopadhyay, S., *et al.* (2010b) Quantitative analysis of fitness and genetic interactions in yeast on a genome scale. *Nat Meth*, **7**(12): 1017–1024.
- Bass, A.J., Thorsson, V., Shmulevich, I., Reynolds, S.M., Miller, M., Bernard, B., Hinoue, T., Laird, P.W., Curtis, C., Shen, H., *et al.* (2014) Comprehensive molecular characterization of gastric adenocarcinoma. *Nature*, **513**(7517): 202–209.
- Bates, D. and Maechler, M. (2016) *Matrix: Sparse and Dense Matrix Classes and Methods*. R package version 1.2-7.1.
- Bateson, W. and Mendel, G. (1909) *Mendel’s principles of heredity, by W. Bateson*. University Press, Cambridge [Eng.].
- Beck, T.F., Mullikin, J.C., and Biesecker, L.G. (2016) Systematic Evaluation of Sanger Validation of Next-Generation Sequencing Variants. *Clin Chem*, **62**(4): 647–654.
- Becker, K.F., Atkinson, M.J., Reich, U., Becker, I., Nekarda, H., Siewert, J.R., and Hfler, H. (1994) E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. *Cancer Research*, **54**(14): 3845–3852.

- Bell, D., Berchuck, A., Birrer, M., Chien, J., Cramer, D., Dao, F., Dhir, R., DiSaia, P., Gabra, H., Glenn, P., *et al.* (2011) Integrated genomic analyses of ovarian carcinoma. *Nature*, **474**(7353): 609–615.
- Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society Series B (Methodological)*, **57**(1): 289–300.
- Berx, G., Cleton-Jansen, A.M., Nollet, F., de Leeuw, W.J., van de Vijver, M., Cornelisse, C., and van Roy, F. (1995) E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. *EMBO J*, **14**(24): 6107–15.
- Berx, G., Cleton-Jansen, A.M., Strumane, K., de Leeuw, W.J., Nollet, F., van Roy, F., and Cornelisse, C. (1996) E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. *Oncogene*, **13**(9): 1919–25.
- Berx, G. and van Roy, F. (2009) Involvement of members of the cadherin superfamily in cancer. *Cold Spring Harb Perspect Biol*, **1**: a003129.
- Bitler, B.G., Aird, K.M., Garipov, A., Li, H., Amatangelo, M., Kossenkova, A.V., Schultz, D.C., Liu, Q., Shih, Ie, M., Conejo-Garcia, J.R., *et al.* (2015) Synthetic lethality by targeting ezh2 methyltransferase activity in arid1a-mutated cancers. *Nat Med*, **21**(3): 231–8.
- Blake, J.A., Christie, K.R., Dolan, M.E., Drabkin, H.J., Hill, D.P., Ni, L., Sitnikov, D., Burgess, S., Buza, T., Gresham, C., *et al.* (2015) Gene Ontology Consortium: going forward. *Nucleic Acids Res*, **43**(Database issue): D1049–1056.
- Boettcher, M., Lawson, A., Ladenburger, V., Fredebohm, J., Wolf, J., Hoheisel, J.D., Frezza, C., and Shlomi, T. (2014) High throughput synthetic lethality screen reveals a tumorigenic role of adenylate cyclase in fumarate hydratase-deficient cancer cells. *BMC Genomics*, **15**: 158.
- Boone, C., Bussey, H., and Andrews, B.J. (2007) Exploring genetic interactions and networks with yeast. *Nat Rev Genet*, **8**(6): 437–49.
- Borgatti, S.P. (2005) Centrality and network flow. *Social Networks*, **27**(1): 55 – 71.
- Boucher, B. and Jenna, S. (2013) Genetic interaction networks: better understand to better predict. *Front Genet*, **4**: 290.

- Breiman, L. (2001) Random forests. *Machine Learning*, **45**(1): 5–32.
- Brin, S. and Page, L. (1998) The anatomy of a large-scale hypertextual web search engine. *Computer Networks and ISDN Systems*, **30**(1): 107 – 117.
- Bryant, H.E., Schultz, N., Thomas, H.D., Parker, K.M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N.J., and Helleday, T. (2005) Specific killing of *BRCA2*-deficient tumours with inhibitors of polyadprribose polymerase. *Nature*, **434**(7035): 913–7.
- Burk, R.D., Chen, Z., Saller, C., Tarvin, K., Carvalho, A.L., Scapulatempo-Neto, C., Silveira, H.C., Fregnani, J.H., Creighton, C.J., Anderson, M.L., *et al.* (2017) Integrated genomic and molecular characterization of cervical cancer. *Nature*, **543**(7645): 378–384.
- Bussey, H., Andrews, B., and Boone, C. (2006) From worm genetic networks to complex human diseases. *Nat Genet*, **38**(8): 862–3.
- Butland, G., Babu, M., Diaz-Mejia, J.J., Bohdana, F., Phanse, S., Gold, B., Yang, W., Li, J., Gagarinova, A.G., Pogoutse, O., *et al.* (2008) esga: E. coli synthetic genetic array analysis. *Nat Methods*, **5**(9): 789–95.
- Cancer Research UK (2017) Family history and cancer genes. <http://www.cancerresearchuk.org/about-cancer/causes-of-cancer/inherited-cancer-genes-and-increased-cancer-risk/family-history-and-inherited-cancer-genes>. Accessed: 22/03/2017.
- Cancer Cell Line Encyclopedia (CCLE) (2014) Broad-Novartis Cancer Cell Line Encyclopedia. <http://www.broadinstitute.org/ccle>. Accessed: 07/11/2014.
- cBioPortal for Cancer Genomics (cBioPortal) (2017) cBioPortal for Cancer Genomics. <http://www.cbioportal.org/>. Accessed: 26/03/2017.
- Cerami, E.G., Gross, B.E., Demir, E., Rodchenkov, I., Babur, O., Anwar, N., Schultz, N., Bader, G.D., and Sander, C. (2011) Pathway Commons, a web resource for biological pathway data. *Nucleic Acids Res*, **39**(Database issue): D685–690.
- Chen, A., Beetham, H., Black, M.A., Priya, R., Telford, B.J., Guest, J., Wiggins, G.A.R., Godwin, T.D., Yap, A.S., and Guilford, P.J. (2014) E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition. *BMC Cancer*, **14**(1): 552.

- Chen, K., Yang, D., Li, X., Sun, B., Song, F., Cao, W., Brat, D.J., Gao, Z., Li, H., Liang, H., *et al.* (2015) Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. *Proc Natl Acad Sci USA*, **112**(4): 1107–1112.
- Chen, S. and Parmigiani, G. (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. *J Clin Oncol*, **25**(11): 1329–1333.
- Chen, X. and Tompa, M. (2010) Comparative assessment of methods for aligning multiple genome sequences. *Nat Biotechnol*, **28**(6): 567–572.
- Cherniack, A.D., Shen, H., Walter, V., Stewart, C., Murray, B.A., Bowlby, R., Hu, X., Ling, S., Soslow, R.A., Broaddus, R.R., *et al.* (2017) Integrated Molecular Characterization of Uterine Carcinosarcoma. *Cancer Cell*, **31**(3): 411–423.
- Chipman, K. and Singh, A. (2009) Predicting genetic interactions with random walks on biological networks. *BMC Bioinformatics*, **10**(1): 17.
- Christofori, G. and Semb, H. (1999) The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. *Trends in Biochemical Sciences*, **24**(2): 73 – 76.
- Ciriello, G., Gatza, M.L., Beck, A.H., Wilkerson, M.D., Rhie, S.K., Pastore, A., Zhang, H., McLellan, M., Yau, C., Kandoth, C., *et al.* (2015) Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. *Cell*, **163**(2): 506–519.
- Clark, M.J. (2004) Endogenous Regulator of G Protein Signaling Proteins Suppress G o-Dependent μ -Opioid Agonist-Mediated Adenylyl Cyclase Supersensitization. *Journal of Pharmacology and Experimental Therapeutics*, **310**(1): 215–222.
- Clough, E. and Barrett, T. (2016) The Gene Expression Omnibus Database. *Methods Mol Biol*, **1418**: 93–110.
- Collingridge, D.S. (2013) A primer on quantitized data analysis and permutation testing. *Journal of Mixed Methods Research*, **7**(1): 81–97.
- Collins, F.S. and Barker, A.D. (2007) Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. *Sci Am*, **296**(3): 50–57.
- Collins, F.S., Morgan, M., and Patrinos, A. (2003) The Human Genome Project: lessons from large-scale biology. *Science*, **300**(5617): 286–290.

- Collisson, E., Campbell, J., Brooks, A., Berger, A., Lee, W., Chmielecki, J., Beer, D., Cope, L., Creighton, C., Danilova, L., *et al.* (2014) Comprehensive molecular profiling of lung adenocarcinoma. *Nature*, **511**(7511): 543–550.
- Corcoran, R.B., Ebi, H., Turke, A.B., Coffee, E.M., Nishino, M., Cogdill, A.P., Brown, R.D., Della Pelle, P., Dias-Santagata, D., Hung, K.E., *et al.* (2012) Egfr-mediated reactivation of mapk signaling contributes to insensitivity of *BRAF*-mutant colorectal cancers to raf inhibition with vemurafenib. *Cancer Discovery*, **2**(3): 227–235.
- Costanzo, M., Baryshnikova, A., Bellay, J., Kim, Y., Spear, E.D., Sevier, C.S., Ding, H., Koh, J.L., Toufighi, K., Mostafavi, S., *et al.* (2010) The genetic landscape of a cell. *Science*, **327**(5964): 425–31.
- Costanzo, M., Baryshnikova, A., Myers, C.L., Andrews, B., and Boone, C. (2011) Charting the genetic interaction map of a cell. *Curr Opin Biotechnol*, **22**(1): 66–74.
- Creighton, C.J., Morgan, M., Gunaratne, P.H., Wheeler, D.A., Gibbs, R.A., Robertson, A., Chu, A., Beroukhim, R., Cibulskis, K., Signoretti, S., *et al.* (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature*, **499**(7456): 43–49.
- Croft, D., Mundo, A.F., Haw, R., Milacic, M., Weiser, J., Wu, G., Caudy, M., Garapati, P., Gillespie, M., Kamdar, M.R., *et al.* (2014) The Reactome pathway knowledgebase. *Nucleic Acids Res*, **42**(database issue): D472D477.
- Crunkhorn, S. (2014) Cancer: Predicting synthetic lethal interactions. *Nat Rev Drug Discov*, **13**(11): 812.
- Csardi, G. and Nepusz, T. (2006) The igraph software package for complex network research. *InterJournal*, **Complex Systems**: 1695.
- Curtis, C., Shah, S.P., Chin, S.F., Turashvili, G., Rueda, O.M., Dunning, M.J., Speed, D., Lynch, A.G., Samarajiwa, S., Yuan, Y., *et al.* (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature*, **486**(7403): 346–352.
- Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., Zhan, J., and Shi, B. (2015) Breast cancer intrinsic subtype classification, clinical use and future trends. *Am J Cancer Res*, **5**(10): 2929–2943.

- Davierwala, A.P., Haynes, J., Li, Z., Brost, R.L., Robinson, M.D., Yu, L., Mnaimneh, S., Ding, H., Zhu, H., Chen, Y., *et al.* (2005) The synthetic genetic interaction spectrum of essential genes. *Nat Genet*, **37**(10): 1147–1152.
- De Leeuw, W.J., Berx, G., Vos, C.B., Peterse, J.L., Van de Vijver, M.J., Litvinov, S., Van Roy, F., Cornelisse, C.J., and Cleton-Jansen, A.M. (1997) Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. *J Pathol*, **183**(4): 404–11.
- Demir, E., Babur, O., Rodchenkov, I., Aksoy, B.A., Fukuda, K.I., Gross, B., Sumer, O.S., Bader, G.D., and Sander, C. (2013) Using biological pathway data with Pax-tools. *PLoS Comput Biol*, **9**(9): e1003194.
- Deshpande, R., Asiedu, M.K., Klebig, M., Sutor, S., Kuzmin, E., Nelson, J., Piotrowski, J., Shin, S.H., Yoshida, M., Costanzo, M., *et al.* (2013) A comparative genomic approach for identifying synthetic lethal interactions in human cancer. *Cancer Res*, **73**(20): 6128–36.
- Dickson, D. (1999) Wellcome funds cancer database. *Nature*, **401**(6755): 729.
- Dienstmann, R. and Tabernero, J. (2011) *BRAF* as a target for cancer therapy. *Anti-cancer Agents Med Chem*, **11**(3): 285–95.
- Dijkstra, E.W. (1959) A note on two problems in connexion with graphs. *Numerische Mathematik*, **1**(1): 269–271.
- Dixon, S.J., Andrews, B.J., and Boone, C. (2009) Exploring the conservation of synthetic lethal genetic interaction networks. *Commun Integr Biol*, **2**(2): 78–81.
- Dixon, S.J., Fedyshyn, Y., Koh, J.L., Prasad, T.S., Chahwan, C., Chua, G., Toufighi, K., Baryshnikova, A., Hayles, J., Hoe, K.L., *et al.* (2008) Significant conservation of synthetic lethal genetic interaction networks between distantly related eukaryotes. *Proc Natl Acad Sci U S A*, **105**(43): 16653–8.
- Dorogovtsev, S.N. and Mendes, J.F. (2003) *Evolution of networks: From biological nets to the Internet and WWW*. Oxford University Press, USA.
- Erdős, P. and Rényi, A. (1959) On random graphs I. *Publ Math Debrecen*, **6**: 290–297.
- Erdős, P. and Rényi, A. (1960) On the evolution of random graphs. In *Publ. Math. Inst. Hung. Acad. Sci*, volume 5, 17–61.

- Eroles, P., Bosch, A., Perez-Fidalgo, J.A., and Lluch, A. (2012) Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. *Cancer Treat Rev*, **38**(6): 698–707.
- Ezkurdia, I., Juan, D., Rodriguez, J.M., Frankish, A., Diekhans, M., Harrow, J., Vazquez, J., Valencia, A., and Tress, M.L. (2014) Multiple evidence strands suggest that there may be as few as 19 000 human protein-coding genes. *Human Molecular Genetics*, **23**(22): 5866.
- Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson, T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., *et al.* (2005) Targeting the dna repair defect in BRCA mutant cells as a therapeutic strategy. *Nature*, **434**(7035): 917–21.
- Fawcett, T. (2006) An introduction to ROC analysis. *Pattern Recognition Letters*, **27**(8): 861 – 874. {ROC} Analysis in Pattern Recognition.
- Fece de la Cruz, F., Gapp, B.V., and Nijman, S.M. (2015) Synthetic lethal vulnerabilities of cancer. *Annu Rev Pharmacol Toxicol*, **55**: 513–531.
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., and Bray, F. (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*, **136**(5): E359–386.
- Fisher, R.A. (1919) Xv.the correlation between relatives on the supposition of mendelian inheritance. *Earth and Environmental Science Transactions of the Royal Society of Edinburgh*, **52**(02): 399–433.
- Fong, P.C., Boss, D.S., Yap, T.A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M.J., *et al.* (2009) Inhibition of poly(adp-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med*, **361**(2): 123–34.
- Fong, P.C., Yap, T.A., Boss, D.S., Carden, C.P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., *et al.* (2010) Poly(adp)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. *J Clin Oncol*, **28**(15): 2512–9.

- Forbes, S.A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., Ding, M., Bamford, S., Cole, C., Ward, S., *et al.* (2015) COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. *Nucleic Acids Res*, **43**(Database issue): D805–811.
- Fraser, A. (2004) Towards full employment: using RNAi to find roles for the redundant. *Oncogene*, **23**(51): 8346–52.
- Futreal, P.A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., and Stratton, M.R. (2004) A census of human cancer genes. *Nat Rev Cancer*, **4**(3): 177–183.
- Futreal, P.A., Kasprzyk, A., Birney, E., Mullikin, J.C., Wooster, R., and Stratton, M.R. (2001) Cancer and genomics. *Nature*, **409**(6822): 850–852.
- Gao, B. and Roux, P.P. (2015) Translational control by oncogenic signaling pathways. *Biochimica et Biophysica Acta*, **1849**(7): 753–65.
- Gatza, M.L., Kung, H.N., Blackwell, K.L., Dewhirst, M.W., Marks, J.R., and Chi, J.T. (2011) Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. *Breast Cancer Res*, **13**(3): R62.
- Gatza, M.L., Lucas, J.E., Barry, W.T., Kim, J.W., Wang, Q., Crawford, M.D., Datto, M.B., Kelley, M., Mathey-Prevot, B., Potti, A., *et al.* (2010) A pathway-based classification of human breast cancer. *Proc Natl Acad Sci USA*, **107**(15): 6994–6999.
- Gatza, M.L., Silva, G.O., Parker, J.S., Fan, C., and Perou, C.M. (2014) An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. *Nat Genet*, **46**(10): 1051–1059.
- Gentleman, R.C., Carey, V.J., Bates, D.M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., *et al.* (2004) Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol*, **5**(10): R80.
- Genz, A. and Bretz, F. (2009) Computation of multivariate normal and t probabilities. In *Lecture Notes in Statistics*, volume 195. Springer-Verlag, Heidelberg.
- Genz, A., Bretz, F., Miwa, T., Mi, X., Leisch, F., Scheipl, F., and Hothorn, T. (2016) *mvtnorm: Multivariate Normal and t Distributions*. R package version 1.0-5. URL.

- Gilbert, W. and Maxam, A. (1973) The nucleotide sequence of the lac operator. *Proceedings of the National Academy of Sciences*, **70**(12): 3581–3584.
- Git, A., Dvinge, H., Salmon-Divon, M., Osborne, M., Kutter, C., Hadfield, J., Bertone, P., and Caldas, C. (2010) Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. *RNA*, **16**(5): 991–1006.
- Globus (Globus) (2017) Research data management simplified. <https://www.globus.org/>. Accessed: 25/03/2017.
- Graziano, F., Humar, B., and Guilford, P. (2003) The role of the E-cadherin gene (*CDH1*) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. *Annals of Oncology*, **14**(12): 1705–1713.
- Güell, O., Sagus, F., and Serrano, M. (2014) Essential plasticity and redundancy of metabolism unveiled by synthetic lethality analysis. *PLoS Comput Biol*, **10**(5): e1003637.
- Guilford, P. (1999) E-cadherin downregulation in cancer: fuel on the fire? *Molecular Medicine Today*, **5**(4): 172 – 177.
- Guilford, P., Hopkins, J., Harraway, J., McLeod, M., McLeod, N., Harawira, P., Taite, H., Scoular, R., Miller, A., and Reeve, A.E. (1998) E-cadherin germline mutations in familial gastric cancer. *Nature*, **392**(6674): 402–5.
- Guilford, P., Humar, B., and Blair, V. (2010) Hereditary diffuse gastric cancer: translation of *CDH1* germline mutations into clinical practice. *Gastric Cancer*, **13**(1): 1–10.
- Guilford, P.J., Hopkins, J.B., Grady, W.M., Markowitz, S.D., Willis, J., Lynch, H., Rajput, A., Wiesner, G.L., Lindor, N.M., Burgart, L.J., *et al.* (1999) E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. *Hum Mutat*, **14**(3): 249–55.
- Guo, J., Liu, H., and Zheng, J. (2016) SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets. *Nucleic Acids Res*, **44**(D1): D1011–1017.
- Hajian-Tilaki, K. (2013) Receiver Operating Characteristic (ROC) Curve Analysis for Medical Diagnostic Test Evaluation. *Caspian J Intern Med*, **4**(2): 627–635.

- Hall, M., Frank, E., Holmes, G., Pfahringer, B., Reutemann, P., and Witten, I.H. (2009) The weka data mining software: an update. *SIGKDD Explor Newsl*, **11**(1): 10–18.
- Hammerman, P.S., Lawrence, M.S., Voet, D., Jing, R., Cibulskis, K., Sivachenko, A., Stojanov, P., McKenna, A., Lander, E.S., Gabriel, S., *et al.* (2012) Comprehensive genomic characterization of squamous cell lung cancers. *Nature*, **489**(7417): 519–525.
- Han, J.D.J., Bertin, N., Hao, T., Goldberg, D.S., Berriz, G.F., Zhang, L.V., Dupuy, D., Walhout, A.J.M., Cusick, M.E., Roth, F.P., *et al.* (2004) Evidence for dynamically organized modularity in the yeast protein-protein interaction network. *Nature*, **430**(6995): 88–93.
- Hanahan, D. and Weinberg, R.A. (2000) The hallmarks of cancer. *Cell*, **100**(1): 57–70.
- Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. *Cell*, **144**(5): 646–674.
- Hanna, S. (2003) Cancer incidence in new zealand (2003-2007). In D. Forman, D. Bray F Brewster, C. Gombe Mbalawa, B. Kohler, M. Piñeros, E. Steliarova-Foucher, R. Swaminathan, and J. Ferlay (editors), *Cancer Incidence in Five Continents*, volume X, 902–907. International Agency for Research on Cancer, Lyon, France. Electronic version <http://ci5.iarc.fr> Accessed 22/03/2017.
- Heiskanen, M., Bian, X., Swan, D., and Basu, A. (2014) caArray microarray database in the cancer biomedical informatics gridTM (caBIGTM). *Cancer Research*, **67**(9 Supplement): 3712–3712.
- Heiskanen, M.A. and Aittokallio, T. (2012) Mining high-throughput screens for cancer drug targets-lessons from yeast chemical-genomic profiling and synthetic lethality. *Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery*, **2**(3): 263–272.
- Hell, P. (1976) Graphs with given neighbourhoods i. problèmes combinatoires at theorie des graphes. *Proc Coil Int CNRS, Orsay*, **260**: 219–223.
- Herschkowitz, J.I., Simin, K., Weigman, V.J., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K.E., Jones, L.P., Assefnia, S., Chandrasekharan, S., *et al.* (2007) Identifi-

- cation of conserved gene expression features between murine mammary carcinoma models and human breast tumors. *Genome Biol*, **8**(5): R76.
- Hillenmeyer, M.E. (2008) The chemical genomic portrait of yeast: uncovering a phenotype for all genes. *Science*, **320**: 362–365.
- Hoadley, K.A., Yau, C., Wolf, D.M., Cherniack, A.D., Tamborero, D., Ng, S., Leiserson, M.D., Niu, B., McLellan, M.D., Uzunangelov, V., *et al.* (2014) Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. *Cell*, **158**(4): 929–944.
- Hoehndorf, R., Hardy, N.W., Osumi-Sutherland, D., Tweedie, S., Schofield, P.N., and Gkoutos, G.V. (2013) Systematic analysis of experimental phenotype data reveals gene functions. *PLoS ONE*, **8**(4): e60847.
- Holm, S. (1979) A simple sequentially rejective multiple test procedure. *Scandinavian Journal of Statistics*, **6**(2): 65–70.
- Holme, P. and Kim, B.J. (2002) Growing scale-free networks with tunable clustering. *Physical Review E*, **65**(2): 026107.
- Hopkins, A.L. (2008) Network pharmacology: the next paradigm in drug discovery. *Nat Chem Biol*, **4**(11): 682–690.
- Hu, Z., Fan, C., Oh, D.S., Marron, J.S., He, X., Qaqish, B.F., Livasy, C., Carey, L.A., Reynolds, E., Dressler, L., *et al.* (2006) The molecular portraits of breast tumors are conserved across microarray platforms. *BMC Genomics*, **7**: 96.
- Huang, E., Cheng, S., Dressman, H., Pittman, J., Tsou, M., Horng, C., Bild, A., Iversen, E., Liao, M., Chen, C., *et al.* (2003) Gene expression predictors of breast cancer outcomes. *Lancet*, **361**: 1590–1596.
- Illumina, Inc (Illumina) (2017) Sequencing and array-based solutions for genetic research. <https://www.illumina.com/>. Accessed: 26/03/2017.
- International HapMap 3 Consortium (HapMap) (2003) The International HapMap Project. *Nature*, **426**(6968): 789–796.
- International Human Genome Sequencing Consortium (IHGSC) (2004) Finishing the euchromatic sequence of the human genome. *Nature*, **431**(7011): 931–945.

- Jerby-Arnon, L., Pfetzer, N., Waldman, Y., McGarry, L., James, D., Shanks, E., Seashore-Ludlow, B., Weinstock, A., Geiger, T., Clemons, P., *et al.* (2014) Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality. *Cell*, **158**(5): 1199–1209.
- Joachims, T. (1999) Making large-scale support vector machine learning practical. In S. Bernhard, Ikonf, J.C.B. Christopher, and J.S. Alexander (editors), *Advances in kernel methods*, 169–184. MIT Press.
- Ju, Z., Liu, W., Roebuck, P.L., Siwak, D.R., Zhang, N., Lu, Y., Davies, M.A., Akbani, R., Weinstein, J.N., Mills, G.B., *et al.* (2015) Development of a robust classifier for quality control of reverse-phase protein arrays. *Bioinformatics*, **31**(6): 912.
- Kaelin, Jr, W. (2005) The concept of synthetic lethality in the context of anticancer therapy. *Nat Rev Cancer*, **5**(9): 689–98.
- Kaelin, Jr, W. (2009) Synthetic lethality: a framework for the development of wiser cancer therapeutics. *Genome Med*, **1**: 99.
- Kakiuchi, M., Nishizawa, T., Ueda, H., Gotoh, K., Tanaka, A., Hayashi, A., Yamamoto, S., Tatsuno, K., Katoh, H., Watanabe, Y., *et al.* (2014) Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. *Nat Genet*, **46**(6): 583–587.
- Kamada, T. and Kawai, S. (1989) An algorithm for drawing general undirected graphs. *Information Processing Letters*, **31**(1): 7–15.
- Kandoth, C., Schultz, N., Cherniack, A.D., Akbani, R., Liu, Y., Shen, H., Robertson, A.G., Pashtan, I., Shen, R., Benz, C.C., *et al.* (2013) Integrated genomic characterization of endometrial carcinoma. *Nature*, **497**(7447): 67–73.
- Kawai, J., Shinagawa, A., Shibata, K., Yoshino, M., Itoh, M., Ishii, Y., Arakawa, T., Hara, A., Fukunishi, Y., Konno, H., *et al.* (2001) Functional annotation of a full-length mouse cDNA collection. *Nature*, **409**(6821): 685–690.
- Kelley, R. and Ideker, T. (2005) Systematic interpretation of genetic interactions using protein networks. *Nat Biotech*, **23**(5): 561–566.
- Kelly, S., Chen, A., Guilford, P., and Black, M. (2017a) Synthetic lethal interaction prediction of target pathways in E-cadherin deficient breast cancers. Submitted to *BMC Genomics*.

- Kelly, S.T. (2013) *Statistical Predictions of Synthetic Lethal Interactions in Cancer*. Dissertation, University of Otago.
- Kelly, S.T., Single, A.B., Telford, B.J., Beetham, H.G., Godwin, T.D., Chen, A., Black, M.A., and Guilford, P.J. (2017b) Towards HDGC chemoprevention: vulnerabilities in E-cadherin-negative cells identified by genome-wide interrogation of isogenic cell lines and whole tumors. Submitted to *Cancer Prev Res*.
- Kozlov, K.N., Gursky, V.V., Kulakovskiy, I.V., and Samsonova, M.G. (2015) Sequence-based model of gap gene regulation network. *BMC Genomics*, **15**(Suppl 12): S6.
- Kranthi, S., Rao, S., and Manimaran, P. (2013) Identification of synthetic lethal pairs in biological systems through network information centrality. *Mol BioSyst*, **9**(8): 2163–2167.
- Lander, E.S. (2011) Initial impact of the sequencing of the human genome. *Nature*, **470**(7333): 187–197.
- Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Devon, K., Dewar, K., Doyle, M., FitzHugh, W., *et al.* (2001) Initial sequencing and analysis of the human genome. *Nature*, **409**(6822): 860–921.
- Langmead, B., Trapnell, C., Pop, M., and Salzberg, S.L. (2009) Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol*, **10**(3): R25.
- Latora, V. and Marchiori, M. (2001) Efficient behavior of small-world networks. *Phys Rev Lett*, **87**: 198701.
- Laufer, C., Fischer, B., Billmann, M., Huber, W., and Boutros, M. (2013) Mapping genetic interactions in human cancer cells with RNAi and multiparametric phenotyping. *Nat Methods*, **10**(5): 427–31.
- Law, C.W., Chen, Y., Shi, W., and Smyth, G.K. (2014) voom: precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biol*, **15**(2): R29.
- Lawrence, M.S., Sougnez, C., Lichtenstein, L., Cibulskis, K., Lander, E., Gabriel, S.B., Getz, G., Ally, A., Balasundaram, M., Birol, I., *et al.* (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature*, **517**(7536): 576–582.

- Le Meur, N. and Gentleman, R. (2008) Modeling synthetic lethality. *Genome Biol*, **9**(9): R135.
- Le Meur, N., Jiang, Z., Liu, T., Mar, J., and Gentleman, R.C. (2014) Slgi: Synthetic lethal genetic interaction. r package version 1.26.0.
- Lee, A.Y., Perreault, R., Harel, S., Boulier, E.L., Suderman, M., Hallett, M., and Jenna, S. (2010a) Searching for signaling balance through the identification of genetic interactors of the rab guanine-nucleotide dissociation inhibitor gdi-1. *PLoS ONE*, **5**(5): e10624.
- Lee, I., Lehner, B., Vavouri, T., Shin, J., Fraser, A.G., and Marcotte, E.M. (2010b) Predicting genetic modifier loci using functional gene networks. *Genome Research*, **20**(8): 1143–1153.
- Lee, I. and Marcotte, E.M. (2009) Effects of functional bias on supervised learning of a gene network model. *Methods Mol Biol*, **541**: 463–75.
- Lee, M.J., Ye, A.S., Gardino, A.K., Heijink, A.M., Sorger, P.K., MacBeath, G., and Yaffe, M.B. (2012) Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. *Cell*, **149**(4): 780–94.
- Lehner, B., Crombie, C., Tischler, J., Fortunato, A., and Fraser, A.G. (2006) Systematic mapping of genetic interactions in *caenorhabditis elegans* identifies common modifiers of diverse signaling pathways. *Nat Genet*, **38**(8): 896–903.
- Li, X.J., Mishra, S.K., Wu, M., Zhang, F., and Zheng, J. (2014) Syn-lethality: An integrative knowledge base of synthetic lethality towards discovery of selective anticancer therapies. *Biomed Res Int*, **2014**: 196034.
- Linehan, W.M., Spellman, P.T., Ricketts, C.J., Creighton, C.J., Fei, S.S., Davis, C., Wheeler, D.A., Murray, B.A., Schmidt, L., Vocke, C.D., *et al.* (2016) Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. *N Engl J Med*, **374**(2): 135–145.
- Lokody, I. (2014) Computational modelling: A computational crystal ball. *Nature Reviews Cancer*, **14**(10): 649–649.
- Lord, C.J., Tutt, A.N., and Ashworth, A. (2015) Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. *Annu Rev Med*, **66**: 455–470.

- Lu, X., Kensche, P.R., Huynen, M.A., and Notebaart, R.A. (2013) Genome evolution predicts genetic interactions in protein complexes and reveals cancer drug targets. *Nat Commun*, **4**: 2124.
- Lu, X., Megchelenbrink, W., Notebaart, R.A., and Huynen, M.A. (2015) Predicting human genetic interactions from cancer genome evolution. *PLoS One*, **10**(5): e0125795.
- Lum, P.Y., Armour, C.D., Stepaniants, S.B., Cavet, G., Wolf, M.K., Butler, J.S., Hinshaw, J.C., Garnier, P., Prestwich, G.D., Leonardson, A., *et al.* (2004) Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. *Cell*, **116**(1): 121–137.
- Luo, J., Solimini, N.L., and Elledge, S.J. (2009) Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction. *Cell*, **136**(5): 823–837.
- Machado, J., Olivera, C., Carvalh, R., Soares, P., Berx, G., Caldas, C., Sercuca, R., Carneiro, F., and Sorbrinho-Simoes, M. (2001) E-cadherin gene (*CDH1*) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. *Oncogene*, **20**: 1525–1528.
- Masciari, S., Larsson, N., Senz, J., Boyd, N., Kaurah, P., Kandel, M.J., Harris, L.N., Pinheiro, H.C., Troussard, A., Miron, P., *et al.* (2007) Germline E-cadherin mutations in familial lobular breast cancer. *J Med Genet*, **44**(11): 726–31.
- Mattison, J., van der Weyden, L., Hubbard, T., and Adams, D.J. (2009) Cancer gene discovery in mouse and man. *Biochim Biophys Acta*, **1796**(2): 140–161.
- Maxam, A.M. and Gilbert, W. (1977) A new method for sequencing DNA. *Proceedings of the National Academy of Science*, **74**(2): 560–564.
- McCourt, C.M., McArt, D.G., Mills, K., Catherwood, M.A., Maxwell, P., Waugh, D.J., Hamilton, P., O’Sullivan, J.M., and Salto-Tellez, M. (2013) Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. *PLoS ONE*, **8**(7): e69604.
- McLachlan, J., George, A., and Banerjee, S. (2016) The current status of parp inhibitors in ovarian cancer. *Tumori*, **102**(5): 433–440.

- McLendon, R., Friedman, A., Bigner, D., Van Meir, E.G., Brat, D.J., Mastrogianakis, G.M., Olson, J.J., Mikkelsen, T., Lehman, N., Aldape, K., *et al.* (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature*, **455**(7216): 1061–1068.
- Miles, D.W. (2001) Update on HER-2 as a target for cancer therapy: herceptin in the clinical setting. *Breast Cancer Res*, **3**(6): 380–384.
- Mortazavi, A., Williams, B.A., McCue, K., Schaeffer, L., and Wold, B. (2008) Mapping and quantifying mammalian transcriptomes by RNA-Seq. *Nat Methods*, **5**(7): 621–628.
- Muzny, D.M., Bainbridge, M.N., Chang, K., Dinh, H.H., Drummond, J.A., Fowler, G., Kovar, C.L., Lewis, L.R., Morgan, M.B., Newsham, I.F., *et al.* (2012) Comprehensive molecular characterization of human colon and rectal cancer. *Nature*, **487**(7407): 330–337.
- Nagalla, S., Chou, J.W., Willingham, M.C., Ruiz, J., Vaughn, J.P., Dubey, P., Lash, T.L., Hamilton-Dutoit, S.J., Bergh, J., Sotiriou, C., *et al.* (2013) Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. *Genome Biol*, **14**(4): R34.
- Neeley, E.S., Kornblau, S.M., Coombes, K.R., and Baggerly, K.A. (2009) Variable slope normalization of reverse phase protein arrays. *Bioinformatics*, **25**(11): 1384.
- Novomestky, F. (2012) *matrixcalc: Collection of functions for matrix calculations*. R package version 1.0-3.
- Oliveira, C., Senz, J., Kaurah, P., Pinheiro, H., Sanges, R., Haegert, A., Corso, G., Schouten, J., Fitzgerald, R., Vogelsang, H., *et al.* (2009) Germline *CDH1* deletions in hereditary diffuse gastric cancer families. *Human Molecular Genetics*, **18**(9): 1545–1555.
- Oliveira, C., Seruca, R., Hoogerbrugge, N., Ligtenberg, M., and Carneiro, F. (2013) Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC). *Eur J Hum Genet*, **21**(8).
- Pandey, G., Zhang, B., Chang, A.N., Myers, C.L., Zhu, J., Kumar, V., and Schadt, E.E. (2010) An integrative multi-network and multi-classifier approach to predict genetic interactions. *PLoS Comput Biol*, **6**(9).

- Parker, J., Mullins, M., Cheung, M., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., *et al.* (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. *Journal of Clinical Oncology*, **27**(8): 1160–1167.
- Peltonen, L. and McKusick, V.A. (2001) Genomics and medicine. Dissecting human disease in the postgenomic era. *Science*, **291**(5507): 1224–1229.
- Pereira, B., Chin, S.F., Rueda, O.M., Vollan, H.K., Provenzano, E., Bardwell, H.A., Pugh, M., Jones, L., Russell, R., Sammut, S.J., *et al.* (2016) Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. *Nat Commun*, **7**: 11908.
- Perou, C.M., Sørlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A., *et al.* (2000) Molecular portraits of human breast tumours. *Nature*, **406**(6797): 747–752.
- Pleasance, E.D., Cheetham, R.K., Stephens, P.J., McBride, D.J., Humphray, S.J., Greenman, C.D., Varela, I., Lin, M.L., Ordonez, G.R., Bignell, G.R., *et al.* (2010) A comprehensive catalogue of somatic mutations from a human cancer genome. *Nature*, **463**(7278): 191–196.
- Polyak, K. and Weinberg, R.A. (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. *Nat Rev Cancer*, **9**(4): 265–73.
- Prahalad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R.L., Bardelli, A., and Bernards, R. (2012) Unresponsiveness of colon cancer to *BRAF*(v600e) inhibition through feedback activation of egfr. *Nature*, **483**(7387): 100–3.
- R Core Team (2016) *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria. R version 3.3.2.
- Ravnan, M.C. and Matala, M.S. (2012) Vemurafenib in patients with *BRAF* v600e mutation-positive advanced melanoma. *Clin Ther*, **34**(7): 1474–86.
- Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., and Smyth, G.K. (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Research*, **43**(7): e47.

- Robin, J.D., Ludlow, A.T., LaRanger, R., Wright, W.E., and Shay, J.W. (2016) Comparison of DNA Quantification Methods for Next Generation Sequencing. *Sci Rep*, **6**: 24067.
- Robinson, M.D. and Oshlack, A. (2010) A scaling normalization method for differential expression analysis of RNA-seq data. *Genome Biol*, **11**(3): R25.
- Roguev, A., Bandyopadhyay, S., Zofall, M., Zhang, K., Fischer, T., Collins, S.R., Qu, H., Shales, M., Park, H.O., Hayles, J., *et al.* (2008) Conservation and rewiring of functional modules revealed by an epistasis map in fission yeast. *Science*, **322**(5900): 405–10.
- Rung, J. and Brazma, A. (2013) Reuse of public genome-wide gene expression data. *Nat Rev Genet*, **14**(2): 89–99.
- Rustici, G., Kolesnikov, N., Brandizi, M., Burdett, T., Dylag, M., Emam, I., Farne, A., Hastings, E., Ison, J., Keays, M., *et al.* (2013) ArrayExpress update—trends in database growth and links to data analysis tools. *Nucleic Acids Res*, **41**(Database issue): D987–990.
- Ryan, C., Lord, C., and Ashworth, A. (2014) Daisy: Picking synthetic lethals from cancer genomes. *Cancer Cell*, **26**(3): 306–308.
- Sander, J.D. and Joung, J.K. (2014) Crispr-cas systems for editing, regulating and targeting genomes. *Nat Biotechnol*, **32**(4): 347–55.
- Sanger, F. and Coulson, A. (1975) A rapid method for determining sequences in dna by primed synthesis with dna polymerase. *Journal of Molecular Biology*, **94**(3): 441 – 448.
- Scheuer, L., Kauff, N., Robson, M., Kelly, B., Barakat, R., Satagopan, J., Ellis, N., Hensley, M., Boyd, J., Borgen, P., *et al.* (2002) Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. *J Clin Oncol*, **20**(5): 1260–1268.
- Semb, H. and Christofori, G. (1998) The tumor-suppressor function of E-cadherin. *Am J Hum Genet*, **63**(6): 1588–93.
- Sing, T., Sander, O., Beerenwinkel, N., and Lengauer, T. (2005) Rocr: visualizing classifier performance in r. *Bioinformatics*, **21**(20): 7881.

- Slurm development team (Slurm) (2017) Slurm workload manager. <https://slurm.schedmd.com/>. Accessed: 25/03/2017.
- Sørlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., *et al.* (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci USA*, **98**(19): 10869–10874.
- Stajich, J.E. and Lapp, H. (2006) Open source tools and toolkits for bioinformatics: significance, and where are we? *Brief Bioinformatics*, **7**(3): 287–296.
- Stratton, M.R., Campbell, P.J., and Futreal, P.A. (2009) The cancer genome. *Nature*, **458**(7239): 719–724.
- Ström, C. and Helleday, T. (2012) Strategies for the use of poly(adenosine diphosphate ribose) polymerase (parp) inhibitors in cancer therapy. *Biomolecules*, **2**(4): 635–649.
- Sun, C., Wang, L., Huang, S., Heynen, G.J.J.E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S.M., *et al.* (2014) Reversible and adaptive resistance to *BRAF*(v600e) inhibition in melanoma. *Nature*, **508**(7494): 118–122.
- Taylor, I.W., Linding, R., Warde-Farley, D., Liu, Y., Pesquita, C., Faria, D., Bull, S., Pawson, T., Morris, Q., and Wrana, J.L. (2009) Dynamic modularity in protein interaction networks predicts breast cancer outcome. *Nat Biotechnol*, **27**(2): 199–204.
- Telford, B.J., Chen, A., Beetham, H., Frick, J., Brew, T.P., Gould, C.M., Single, A., Godwin, T., Simpson, K.J., and Guilford, P. (2015) Synthetic lethal screens identify vulnerabilities in gpcr signalling and cytoskeletal organization in E-cadherin-deficient cells. *Mol Cancer Ther*, **14**(5): 1213–1223.
- The 1000 Genomes Project Consortium (1000 Genomes) (2010) A map of human genome variation from population-scale sequencing. *Nature*, **467**(7319): 1061–1073.
- The Cancer Genome Atlas Research Network (TCGA) (2012) Comprehensive molecular portraits of human breast tumours. *Nature*, **490**(7418): 61–70.
- The Cancer Genome Atlas Research Network (TCGA) (2017a) The Cancer Genome Atlas Project. <https://cancergenome.nih.gov/>. Accessed: 26/03/2017.

- The Cancer Genome Atlas Research Network (TCGA) (2017b) The Cancer Genome Atlas Project Data Portal. <https://tcga-data.nci.nih.gov/>. Accessed: 06/02/2017 (via cBioPortal).
- The Cancer Society of New Zealand (Cancer Society of NZ) (2017) What is cancer? <https://otago-southland.cancernz.org.nz/en/cancer-information/other-links/what-is-cancer-3/>. Accessed: 22/03/2017.
- The Catalogue Of Somatic Mutations In Cancer (COSMIC) (2016) Cosmic: The catalogue of somatic mutations in cancer. <http://cancer.sanger.ac.uk/cosmic>. Release 79 (23/08/2016), Accessed: 05/02/2017.
- The Comprehensive R Archive Network (CRAN) (2017) Cran. <https://cran.r-project.org/>. Accessed: 24/03/2017.
- The ENCODE Project Consortium (ENCODE) (2004) The ENCODE (ENCyclopedia Of DNA Elements) Project. *Science*, **306**(5696): 636–640.
- The International Cancer Genome Consortium (ICGC) (2017) ICGC Data Portal. <https://dcc.icgc.org/>. Accessed: 06/02/2017.
- The National Cancer Institute (NCI) (2015) The genetics of cancer. <https://www.cancer.gov/about-cancer/causes-prevention/genetics>. Published: 22/04/2015, Accessed: 22/03/2017.
- The New Zealand eScience Infrastructure (NeSI) (2017) NeSI. <https://www.nesi.org.nz/>. Accessed: 25/03/2017.
- The Pharmaceutical Management Agency (PHARMAC) (2016) Approval of multi-product funding proposal with roche.
- Tierney, L., Rossini, A.J., Li, N., and Sevcikova, H. (2015) *snow: Simple Network of Workstations*. R package version 0.4-2.
- Tiong, K.L., Chang, K.C., Yeh, K.T., Liu, T.Y., Wu, J.H., Hsieh, P.H., Lin, S.H., Lai, W.Y., Hsu, Y.C., Chen, J.Y., *et al.* (2014) Csnk1e/ctnnb1 are synthetic lethal to tp53 in colorectal cancer and are markers for prognosis. *Neoplasia*, **16**(5): 441–50.
- Tischler, J., Lehner, B., and Fraser, A.G. (2008) Evolutionary plasticity of genetic interaction networks. *Nat Genet*, **40**(4): 390–391.

- Tomasetti, C. and Vogelstein, B. (2015) Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. *Science*, **347**(6217): 78–81.
- Tong, A.H., Evangelista, M., Parsons, A.B., Xu, H., Bader, G.D., Page, N., Robinson, M., Raghibizadeh, S., Hogue, C.W., Bussey, H., *et al.* (2001) Systematic genetic analysis with ordered arrays of yeast deletion mutants. *Science*, **294**(5550): 2364–8.
- Tong, A.H., Lesage, G., Bader, G.D., Ding, H., Xu, H., Xin, X., Young, J., Berriz, G.F., Brost, R.L., Chang, M., *et al.* (2004) Global mapping of the yeast genetic interaction network. *Science*, **303**(5659): 808–13.
- Travers, J. and Milgram, S. (1969) An experimental study of the small world problem. *Sociometry*, **32**(4): 425–443.
- Tsai, H.C., Li, H., Van Neste, L., Cai, Y., Robert, C., Rassool, F.V., Shin, J.J., Harbom, K.M., Beaty, R., Pappou, E., *et al.* (2012) Transient low doses of dna-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. *Cancer Cell*, **21**(3): 430–46.
- Tutt, A., Robson, M., Garber, J.E., Domchek, S.M., Audeh, M.W., Weitzel, J.N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R.K., *et al.* (2010) Oral poly(adp-ribose) polymerase inhibitor olaparib in patients with *BRCA1* or *BRCA2* mutations and advanced breast cancer: a proof-of-concept trial. *Lancet*, **376**(9737): 235–44.
- van der Meer, R., Song, H.Y., Park, S.H., Abdulkadir, S.A., and Roh, M. (2014) RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition. *Clinical Cancer Research*, **20**(12): 3211–3221.
- van Steen, K. (2012) Travelling the world of genegene interactions. *Briefings in Bioinformatics*, **13**(1): 1–19.
- van Steen, M. (2010) *Graph Theory and Complex Networks: An Introduction*. Maarten van Steen, VU Amsterdam.
- Vapnik, V.N. (1995) *The nature of statistical learning theory*. Springer-Verlag New York, Inc.
- Vargas, J.J., Gusella, G., Najfeld, V., Klotman, M., and Cara, A. (2004) Novel integrase-defective lentiviral episomal vectors for gene transfer. *Hum Gene Ther*, **15**: 361–372.

- Vizeacoumar, F.J., Arnold, R., Vizeacoumar, F.S., Chandrashekhar, M., Buzina, A., Young, J.T., Kwan, J.H., Sayad, A., Mero, P., Lawo, S., *et al.* (2013) A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. *Mol Syst Biol*, **9**: 696.
- Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A., and Kinzler, K.W. (2013) Cancer genome landscapes. *Science*, **339**(6127): 1546–1558.
- Vos, C.B., Cleton-Jansen, A.M., Berx, G., de Leeuw, W.J., ter Haar, N.T., van Roy, F., Cornelisse, C.J., Peterse, J.L., and van de Vijver, M.J. (1997) E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. *Br J Cancer*, **76**(9): 1131–3.
- Wang, K., Singh, D., Zeng, Z., Coleman, S.J., Huang, Y., Savich, G.L., He, X., Mieczkowski, P., Grimm, S.A., Perou, C.M., *et al.* (2010) MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. *Nucleic Acids Res*, **38**(18): e178.
- Wang, K., Yuen, S.T., Xu, J., Lee, S.P., Yan, H.H., Shi, S.T., Siu, H.C., Deng, S., Chu, K.M., Law, S., *et al.* (2014) Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. *Nat Genet*, **46**(6): 573–582.
- Wang, X. and Simon, R. (2013) Identification of potential synthetic lethal genes to p53 using a computational biology approach. *BMC Medical Genomics*, **6**(1): 30.
- Wappett, M. (2014) Bisep: Toolkit to identify candidate synthetic lethality. r package version 2.0.
- Wappett, M., Dulak, A., Yang, Z.R., Al-Watban, A., Bradford, J.R., and Dry, J.R. (2016) Multi-omic measurement of mutually exclusive loss-of-function enriches for candidate synthetic lethal gene pairs. *BMC Genomics*, **17**: 65.
- Warnes, G.R., Bolker, B., Bonebakker, L., Gentleman, R., Liaw, W.H.A., Lumley, T., Maechler, M., Magnusson, A., Moeller, S., Schwartz, M., *et al.* (2015) *gplots: Various R Programming Tools for Plotting Data*. R package version 2.17.0.
- Watts, D.J. and Strogatz, S.H. (1998) Collective dynamics of 'small-world' networks. *Nature*, **393**(6684): 440–2.
- Weinstein, I.B. (2000) Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. *Carcinogenesis*, **21**(5): 857–864.

- Weinstein, J.N., Akbani, R., Broom, B.M., Wang, W., Verhaak, R.G., McConkey, D., Lerner, S., Morgan, M., Creighton, C.J., Smith, C., *et al.* (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. *Nature*, **507**(7492): 315–322.
- Weinstein, J.N., Collisson, E.A., Mills, G.B., Shaw, K.R., Ozenberger, B.A., Ellrott, K., Shmulevich, I., Sander, C., Stuart, J.M., Chang, K., *et al.* (2013) The Cancer Genome Atlas Pan-Cancer analysis project. *Nat Genet*, **45**(10): 1113–1120.
- Wickham, H. and Chang, W. (2016) *devtools: Tools to Make Developing R Packages Easier*. R package version 1.12.0.
- Wickham, H., Danenberg, P., and Eugster, M. (2017) *roxygen2: In-Line Documentation for R*. R package version 6.0.1.
- Wong, S.L., Zhang, L.V., Tong, A.H.Y., Li, Z., Goldberg, D.S., King, O.D., Lesage, G., Vidal, M., Andrews, B., Bussey, H., *et al.* (2004) Combining biological networks to predict genetic interactions. *Proceedings of the National Academy of Sciences of the United States of America*, **101**(44): 15682–15687.
- World Health Organization (WHO) (2017) Fact sheet: Cancer. <http://www.who.int/mediacentre/factsheets/fs297/en/>. Updated February 2017, Accessed: 22/03/2017.
- Wu, M., Li, X., Zhang, F., Li, X., Kwoh, C.K., and Zheng, J. (2014) In silico prediction of synthetic lethality by meta-analysis of genetic interactions, functions, and pathways in yeast and human cancer. *Cancer Inform*, **13**(Suppl 3): 71–80.
- Yu, H. (2002) Rmpi: Parallel statistical computing in r. *R News*, **2**(2): 10–14.
- Zhang, F., Wu, M., Li, X.J., Li, X.L., Kwoh, C.K., and Zheng, J. (2015) Predicting essential genes and synthetic lethality via influence propagation in signaling pathways of cancer cell fates. *J Bioinform Comput Biol*, **13**(3): 1541002.
- Zhang, J., Baran, J., Cros, A., Guberman, J.M., Haider, S., Hsu, J., Liang, Y., Rivkin, E., Wang, J., Whitty, B., *et al.* (2011) International cancer genome consortium data portala one-stop shop for cancer genomics data. *Database: The Journal of Biological Databases and Curation*, **2011**: bar026.
- Zhong, W. and Sternberg, P.W. (2006) Genome-wide prediction of c. elegans genetic interactions. *Science*, **311**(5766): 1481–1484.

Zweig, M.H. and Campbell, G. (1993) Receiver-operating characteristic (roc) plots: a fundamental evaluation tool in clinical medicine. *Clinical Chemistry*, **39**(4): 561–577.